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1. RESUMO
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Introdução: A insuficiência cardíaca (IC) está associada com morbilidade importante, redução da 
qualidade de vida e custos elevados realcionados funamentalmente com hospitalizações. Os objecti-
vos do tratamento em doentes com diagnóstico estabelecido são o controlo dos sintomas, a pre-
venção da hospitalização e a melhoria da sobrvivência. A terapêutica diurética é necessária para o 
tratamento sintomático dos doentes com  IC mas o papel da adesão à terapêutica na prevenção das 
hospitalizações não está completamente esclarecido. A aplicação de estudos observacionais podem 
ser muito úteis neste âmbito. 
Objectivos: Quantificação do efeito da baixa adesão à terapêutica diurética como factor precipitante 
de descompensação de IC crónica. 
Métodos: Para avaliar o efeito da baixa adesão à terapêutica foi desenhado um estudo case-time-
control. Este desenho é constituído por um case-crossover de casos - doentes admitidos num hospi-
tal universitário terciário, entre Maio de 2009  e Janeiro de 2011 por IC crónica descompensada 
(n=325) - e um  case-crossover  de controlos constituído pela selecção de um grupo controlo inde-
pendente - doente com IC crónica estável seguidos na consulta externa especializada em IC do 
mesmo hospital entre Janeiro de 2011 e Julho de 2012 (n=292). Todos os doentes incluídos estavam 
tratados com diurético de ansa - furosemida. A adesão foi avaliada com recurso a um questionário 
semi-quantitativo e classificada como baixa se o número de tomas de furosemida fosse inferior a 
88% da dose semanal prescrita. Para estimar o efeito da baixa adesão foi utilizou-se  regressão logís-
tica condicional. A razão entre o OR do grupo caso e o OR do grupo controlo permite estimar o OR 
do estudo case-time-control. 
Resultado: Os casos eram mais velhos, predominantemente mulheres e apresentavam disfunção 
sistólica ventricular esquerda (DSVE) grave de mais frequentemente de etiologia isquémica. A pre-
valência de fatores de risco e comorbilidades era maior nos casos, incluindo a prevalência de hiper-
tensão arterial, diabetes mellitus, fibrilhação auricular, doença pulmonar obstrutiva crónica e anemia, 
com excepção da prevalência de doença renal crónica. Os casos estavam menos frequentemente 
tratados com inibidores da enzima de conversão da angiotensina (IECA) ou bloqueadores-beta. A 
prevalência da baixa adesão era de 17% (108  doentes) nos casos e 15% (86  doentes) nos controlos. 
Entre os casos, a baixa adesão à terapêutica diurética estava 3  vezes aumentada e era significativa-
mente mais provável na semana anterior à hospitalização do que 4 semanas antes (OR=3.00, 95% CI 
1.09–8.25, p=0.033). Entre os controlos as diferenças reportadas relativamente à adesão eram me-
nores e não significativas (OR=1.50, 95% CI 0.72–3.11, 0.277). O OR do estudo case-time-control 
para baixa adesão correspondeu a 2.00. he case-time-control OR for low adherence was 2.00. O 
efeito trigger da baixa adesão era mais forte entre doentes mais  velhos, nas mulheres, com DSVE 
grave, sem factores de risco ou comorbilidades e medicados com IECA.  
Conclusões: Uma taxa de adesão inferior a 88% das doses previstas de diurético de ansa em doen-
tes com IC crónica duplica o risco de descompensação na semana seguinte. A identificação de gru-
pos de doentes mais suceptíveis ao efeito da baixa adesão pode permitir a instituição de atempada 
de medidas de melhoria da adesão à terapêutica.
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2. ABSTRACT
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Introduction: Heart failure (HF) is associated with substantial morbidity, impaired quality of life and hu-
ge costs, in large part related with hospitalizations. The goals of treatment in patients with established 
HF are symptoms and signs relief, prevention of hospital admission and improvement in survival. Diu-
retics are required for the symptomatic management of HF but the role of therapy adherence in pre-
venting hospital admissions is incompletely understood. Observational studies may be a valuable help 
to address these questions.
Objectives: To quantify the effect of low adherence to loop diuretic therapy as triggering factor for 
chronic HF decompensation. 
Methods: To assess the effect of low adherence we performed a case-time-control study. It compri-
ses a regular case-crossover of cases - patients admited at a teaching tertiary care hospital, between 
May 2009 and January 2011 due to decompensated chronic HF (n=325) - and a case-crossover of 
controls with a selection of an independent control group - stable chronic HF patients followed at the 
HF outpatient clinic of the same hospital between January 2011 and July 2012 (n=292). All patients 
included were treated with loop diuretic furosemide. Adherence was assessed by a semi-quantitative 
questionnaire and classified as low if less than 88% of prescribed doses were taken in the preceding 
week. In order to calculate these effects we have used conditional logistic regression. The ratio bet-
ween the OR from the case arm study by the OR obtained in the control arm will provide the case-ti-
me-control study OR risk for acute decompensated HF if low adherence. In order to calculate these 
effects we have used conditional logistic regression. 
Results: Case patients were older, most were women and with severe left ventricular systolic dysfunc-
tion (LVSD) from ischemic etiology. Risk factors and comorbidities prevalence was higher in cases, 
including arterial hypertension, diabetes mellitus, atrial fibrillation, chronic obstrutive pulmonary disea-
se and anemia, with the exception of chronic kidney disease. Cases were less frequently treated with 
angiotensin converting enzyme inhibitors (ACEI) or beta-blockers. The prevalence of low adherence 
was 17% (108  patients) in the case arm and 15% (86 patients) in the control arm. Among cases, low 
adherence to diuretic therapy was 3-fold and significantly more likely in the week preceding hospitali-
zation than 4 weeks earlier (OR=3.00, 95% CI 1.09–8.25, p=0.033). Among controls, the difference in 
reported adherence was smaller and non-significant (OR=1.50, 95% CI 0.72–3.11, 0.277). The case-
time-control OR for low adherence was 2.00. This triggering effect was stronger among older pa-
tients, in women, with severe LVSD, without risk factors and comorbidities, and under treatment with 
ACEI. 
Conclusions: An adherence rate below 88% dose-counts of loop diuretic in chronic HF patients dou-
bles the risk of decompensation in the following week. The identification of patient groups in which 
low adherence effect is stronger may enable timely application of adherence improvement measures.
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3. INTRODUCTION
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    Cardiovascular diseases are the number one cause of death globally: more people die annually from 
cardiovascular diseases than from any other cause[1]. An estimated 17.3  million people died from 
cardiovascular diseases in 2008, representing 30% of all global deaths[1]. Of these deaths, an esti-
mated 7.3 million were due to coronary heart disease and 6.2 million were due to stroke[2].
    Heart failure (HF) has become a leading cause of death and morbidity worldwide[2-5]. In developed 
countries symptomatic HF occurs in 1-2% of the adult population, 6-10% of people aged over 65 
years and more than 10% of people aged over 70 years[5, 6]. HF is associated with substantial mor-
bidity, impaired quality of life and huge costs, in large part related with hospitalizations[6]. 
    HF can be defined as an abnormality of cardiac structure or function leading to failure of the heart to 
deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues at normal 
filling pressures [5, 7]. May present acutely, with occurrence of severe symptoms and signs within 24 
hours[8] but generally it is a chronic condition in which worsening of symptoms and signs can occur 
and may require hospitalization or more frequent recurrence to medical care (decompensation of 
chronic HF (CHF). 
    Clinically, HF is defined as a syndrome in which patients have typical symptoms (e.g. breathlessness, 
ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary crackles, and 
displaced apex beat) resulting from an abnormality of cardiac structure or function[5, 7]. 
  The diagnosis of HF, especially when relying solely on symptoms and signs (which is  often the case 
in primary care), is difficult because there is no single diagnostic test for HF: it is largely a clinical diag-
nosis based on a careful history and physical examination. So, the diagnosis of HF can be difficult as 
many of the symptoms of HF are non-discriminating and, therefore, of limited diagnostic value[5, 8]. 
The clinical syndrome of HF may result from disorders of the pericardium, myocardium, endocardium, 
heart valves, or great vessels or from certain metabolic abnormalities, but most patients with HF have 
symptoms due to impaired LV myocardial function[7]. 
3.1 Definitions
Chronic heart failure (CHF)
  A chronic heart failure (CHF) patient is usually a treated patient with previous diagnosis of HF. CHF 
patients are considered ‘stable’ if their symptoms and signs have remained generally unchanged for 
at least one month[5, 7]. 
Acute heart failure syndromes (AHFS)
  The acute HF syndromes (AHFS) have a heterogeneous presentation that makes the development of 
a comprehensive classification scheme difficult (Fig. 1). 
  New-onset or de novo HF occurs in approximately 20% of all AHFS admissions when patients pre-
sent for the first time with symptoms of HF. They may have no prior history of cardiovascular disease 
or risk factors (e.g., acute myocarditis); but more commonly, they have a background of risk factors 
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for HF (HF stage A according to the ACC/AHA guidelines) or pre-existing asymptomatic structural 
heart disease (HF stage B  according to the ACC/AHA guidelines). Many of these patients develop 
AHFS in the setting of acute coronary syndromes (ACS). 
  Worsening chronic HF occurs in patients who have a history of CHF (HF stage C according to the 
ACC/AHA guidelines) and present with an episode of decompensation. This group accounts for the 
majority (approximately 80%) of patients hospitalized with AHFS. Such patients may have easily iden-
tifiable precipitants or no clear explanation for decompensation. A subgroup of these patients (10% to 
15%) has advanced or end-stage HF defined as refractoriness to available therapies (ACC/AHA stage 
D). In these advanced HF patients, hospitalization may be triggered by severe chronic symptoms 
rather than by an abrupt change in clinical condition[7]. The history and physical examination allows 
estimation of a patient’s hemodynamic status, that is, the degree of congestion (“dry” versus “wet”), 
as well as the adequacy of their peripheral perfusion (“warm” versus “cold”) which has implications on 
further stratification of the patient[9].
              
Fig. 1 – Clinical profiles of acute heart failure presentation. (Adapted from: Nohria A, et al. JAMA. 2002;287(5):628-640).
  The main terminology used to describe HF is historical and is  based on measurement of left ventricu-
lar (LV) ejection fraction (EF). Mathematically, EF is  the stroke volume (which is the end-diastolic vol-
ume minus the end-systolic volume) divided by the end-diastolic volume. In patients with reduced 
contraction and emptying of the left ventricle (i.e. systolic dysfunction), stroke volume is maintained by 
an increase in end-diastolic volume (because the left ventricle dilates), i.e. the heart ejects a smaller 
fraction of a larger volume. The more severe the systolic dysfunction, the more the EF is  reduced from 
normal and, generally, the greater the end-diastolic and end-systolic volumes[5, 7]. The EF is consid-
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ered important in HF, not only because of its prognostic importance but also because most clinical 
trials selected patients based upon EF[5, 7]. 
Heart failure with reduced ejection fraction (HF-REF)
  At least half of patients with HF have a reduced EF (HF-REF)[5, 7, 10]. The definition of HF-REF has 
varied, with cut-off values of left ventricular ejection fraction (LVEF) set as ≤35%, <40%, and ≤40% [5, 
7, 10]. Randomized clinical trials  in patients with HF have mainly enrolled patients with HF-REF with 
an EF ≤35% or ≤40%, and it is only in these patients that efficacious therapies have been demon-
strated to date. According to HF guidelines of the European Society of Cardiology, HF-REF is defined 
as the clinical diagnosis of HF and EF ≤40%[5, 7]. 
Heart failure with preserved ejection fraction (HF-PEF)
  Until the last two decades, the possibility that large numbers of patients with HF might have a normal 
EF was not considered. Consensus seems to be building toward use of an EF higher than 50% to 
designate HF-PEF classification[11]. As numerous studies have now demonstrated, HF-PEF is com-
mon suggesting it contributes significantly to the huge burden of disease caused by HF[12]. A number 
of recent community-based epidemiological studies of HF have suggested that 30% to 50% of cases 
of HF have preserved LV systolic function. The diagnosis of HF-PEF is more difficult than the diagnosis 
of HF-REF because it is largely one of exclusion, i.e. potential non-cardiac causes of the patient’s 
symptoms (such as anemia or chronic lung disease) must first be excludeded[5].
  It is often assumed that HF-PEF cases represent diastolic HF (DHF) [13-15]. However, careful inter-
pretation of the data must be made because the gold standard for defining diastolic dysfunction is left 
heart catheterization and evaluation of pressure-volume curves at rest and during exercise which is 
not feasible as an investigative tool for the majority of patients[13]. Currently, a diagnosis of DHF is 
often made as a result of a patient presenting with symptoms and signs suggestive of HF in whom LV 
systolic dysfunction is subsequently excluded[13] which may not be the most correct assumption.
  HF-PEF seems to have a different epidemiological and etiological profile from HF-REF. Patients with 
HF-PEF are older and more often female and obese than those with HF-REF. They are less likely to 
have coronary heart disease and more likely to have hypertension and atrial fibrillation (AF)[16-18]. 
Functional classification
  Both the American College of Cardiology/American Heart Association (ACC/AHA) stages of HF and 
the New York Heart Association (NYHA) functional classification provide useful and complementary 
information about the presence and severity of HF (Fig. 2). The ACC/AHA stages of HF emphasize the 
development and progression of disease and can be used to describe individuals and populations, 
whereas the NYHA classes focus on exercise capacity and the symptomatic status of the disease[5, 
7, 19]. 
  The ACC/AHA stages of HF recognize that both risk factors and abnormalities of cardiac structure 
are associated with HF. Progression across HF stages is associated with reduced 5-year survival and 
increased plasma natriuretic peptide concentrations. Therapeutic interventions in each stage aim at 
modifying risk factors (stage A), treating structural heart disease (stage B), and reducing morbidity and 
mortality (stages C and D) should be implemented. The NYHA functional classification gauges the se-
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verity of symptoms in those with structural heart disease, primarily stages C and D. It is a subjective 
assessment by a clinician and can change frequently over short periods of time. Although reproduci-
bility and validity may be problematic [20], the NYHA functional classification is an independent pre-
dictor of mortality. It is widely used in clinical practice and research and for determining the eligibility of 
patients for certain healthcare services[7, 11]. 
  
  
Fig. 2 – Functional classifications for HF severity evaluation: New York Heart Association (NYHA) classification and American College of 
Cardiology/American Heart Association (ACC/AHA) classification. (Adapted from: McMurray JJ, et al. Eur Heart J, 2012. 33(14): p. 
1787-847.[5]; Jessup M. N Engl J Med 2003; 348:2007-2018).
3.2 Burden of disease
Prevalence
  On the basis of data from NHANES 2005–2008, there is an estimated 5.7 million Americans older 
than 20 years that have HF and projections of crude prevalence showed that in 2010, 6.6 million 
Americans adults older than 18  years  of age (2.8%) had HF. It is estimated that by 2030, an additional 
3  million people will have HF, a 25% increase in prevalence from 2010[21, 22]. Data from the WHO 
suggest that the prevalence of HF differs little around the world[1].
Incidence
  According to the WHO’s global burden of disease report[23] of 2004, updated in 2008, the incidence 
of congestive HF due to rheumatic heart disease, hypertensive heart disease, ischemic heart disease 
or inflammatory heart diseases is, in millions, 5.7 globally, 0.5 in Africa, 0.8  in the Americas, 0.4 in 
Eastern Mediterranean, 1.3 in Europe and 1.4 in South-East Asia and 1.3 in Western Pacific[23].
  HF incidence approaches 10 per 1000 population after 65 years of age and 75% have history of hy-
pertension. At 40 years of age, the lifetime risk of developing HF for both men and women is 1 in 5. At 
80 years of age, the remaining lifetime risk for development of new HF remains at 20% for men and 
women, even in the face of a much shorter life expectancy. At 40 years of age, the lifetime risk of HF 
occurring without antecedent myocardial infarction is 1 in 9 for men and 1 in 6 for women. The lifetime 
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risk for people with blood pressure 160/90 mmHg is double that of those with blood pressure 140/90 
mmHg[21, 24]. 
  The incidence differs according to ethnicity. In MESA study, African Americans had the highest risk of 
developing HF, followed by Hispanic, White, and Chinese Americans (4.6, 3.5, 2.4, and 1.0 per 1000 
person-years, respectively). This higher risk reflected differences in the prevalence of hypertension, 
diabetes mellitus (DM), and socioeconomic status. African Americans had the highest proportion of 
incident HF not preceded by clinical MI (75%)[21, 25]. The higher HF incidence in blacks may be ex-
plained largely by the presence of higher levels of atherosclerotic risk factors[21, 26].
  Data from Kaiser Permanente showed an increase in the incidence of HF among the elderly, with the 
effect being greater in men[21, 27]. In the CARDIA study, HF before 50 years of age was more com-
mon among blacks than whites. Hypertension, obesity, and systolic dysfunction are important risk 
factors that may be targets for prevention[21, 28]. In Olmsted County, Minnesota, the incidence of HF 
did not decline between 1979 and 2000[21, 29].
Mortality
  The 2009 overall death rate for HF was 82.3. Any-mention death rates were 98.3  for white males, 
104.5 for black males, 72.2 for white females, and 79.7 for black females. One in nine deaths has HF 
mentioned on the death certificate. The number of any-mention deaths from HF was approximately as 
high in 1995 (287 000) as it was in 2009 (275 000)[21]. In-hospital mortality seems to be improv-
ing[20].
Hospitalizations
  HF is the primary diagnosis in >1 million hospitalizations annually[21]. Patients hospitalized for HF are 
at high risk for all-cause re-hospitalization, with a 1-month readmission rate of 25%[7]. Presently, HF is 
the leading cause of hospitalization among patients > 65 years of age[21]; the largest percentage of 
expenditures related to HF are directly attributable to hospital costs. Moreover, in addition to costs, 
hospitalization for acutely decompensated HF represents a sentinel prognostic event in the course of 
many patients with HF, with a high risk for recurrent hospitalization (e.g., 50% at 6 months) and a 1-
year mortality rate of approximately 30%[30, 31].
  Community studies indicate that although the incidence of HF has remained stable over time, sur-
vival has improved, leading to an increase in the prevalence of HF in the United States [29, 32, 33], 
which suggests that the increase in HF hospitalizations reflects, in part, the larger population of pa-
tients. Yet, little is  known about the burden of hospitalization among HF patients, including the rate 
and cumulative number of hospitalizations per patient that occur after HF diagnosis and whether tem-
poral changes have occurred. Studies have suggested that readmission rates are high in patients with 
a prior HF admission[32].
  Also, little is known about the etiology of hospitalizations among HF patients. Fang et al.[34] per-
formed an evaluation of hospitalizations from the National Hospital Discharge Survey from 1979 
through 2004. They found that the proportion of hospitalizations with HF as a first-listed diagnosis re-
mained at approximately 30% over the study period. However, there was a decline in the proportion 
of admissions due to coronary or other cardiovascular diseases, and an increase in the proportion 
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due to non-cardiovascular diseases[32]. Curtis  et al.[35] examined hospital readmission rates among 
Medicare beneficiaries hospitalized with HF from 2001 through 2005 and found that approximately 
27% of readmissions were due to HF. This  analysis did not include patients without a prior HF hospi-
talization and only examined the first readmission, and thus cannot provide information on the total 
burden of hospitalizations. To date, the cause of hospitalization among community HF patients, and 
potential temporal changes, remain unclear[32].
  Certainly, HF admission has emerged as a risk factor for hospital readmission[35]. However, despite 
multiple studies, no consistent predictors of readmission among patients with HF have emerged[35]. 
No studies have examined predictors of admission using incident-validated HF patients followed for a 
prolonged time period or used modeling techniques to account for repeated hospitalizations after HF 
diagnosis. As HF is a chronic disease characterized by periodic exacerbations often leading to multi-
ple hospitalizations, analyzing only the first rehospitalization excludes information from subsequent 
hospitalizations[32]. In Dunlay et. al [32] study, independent risk factors  for all cause admissions after 
HF diagnosis were male sex, diabetes mellitus, chronic obstructive pulmonary disease (COPD), ane-
mia, and reduced creatinine clearance at HF diagnosis. Detection of these factors among newly diag-
nosed HF patients may help in identifying those at higher risk for multiple admissions and for whom 
more intense care is needed. The fact that most hospitalizations among HF patients are due to non-
HF causes underscores the urgent need to determine whether targeting comorbidities could lead to a 
decrease in hospitalizations[32].
  Hospitalization for HF is a growing and major public health issue. Data from HF registries have clari-
fied the profile of patients with HF requiring hospitalization [30, 31, 36, 37]. Characteristically, such 
patients are elderly or near elderly, equally male or female, and typically have a history of hypertension, 
as well as other medical comorbidities, including chronic kidney disease, hyponatremia, hematologic 
abnormalities, and COPD [36, 38-40]. A relatively equal percentage of patients with acutely decom-
pensated HF have impaired versus preserved left ventricular systolic function [41, 42].
  Hospital discharges for HF were essentially unchanged from 1999 to 2009, with first-listed dis-
charges of 975 000 and 1 094 000, respectively. In 2009, there were 3  041 000 physician office visits 
with a primary diagnosis of HF. In 2009, there were 668  000 emergency department visits and 293 
000 outpatient department visits for HF[21, 32]. 
Disability
  From the global burden of disease report the severity weight for HF disabling sequelae and injury is 
0.24 - 0.36 and in class IV (in a scale 0-1, divided in seven classes). The impact of any disease state 
has to be measured not only in terms of absolute mortality rates, but the average age of those af-
fected, its effect on quality of life and the type and cost of health-care resources it typically en-
genders[12]. With the notable exception of lung cancer, HF is as ‘malignant’ as many common types 
of cancer and is associated with a comparable number of expected life-years lost[12]. In fact, the 
Scottish data from Stewart et. al show that patients admitted to hospital with a diagnosis of cancer 
often survive longer than those with a diagnosis of HF[18]. As such, for both men and women, HF se-
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vere enough to require hospitalization is more ‘malignant’ than many of the common types of can-
cer[12]. 
Comorbidities
  A large proportion of readmissions for HF are associated with comorbidities that precipitate, contrib-
ute to, or complicate HF admission,[32, 43] especially in the elderly. In a recent population study, 39% 
of HF patients had ≥5 non-cardiac comorbidities and only 4% had HF alone[32, 44].
Quality of life
  The health related quality of life (HRQOL) is reduced in HF, especially in the areas of physical func-
tioning and vitality. Lack of improvement in HRQOL after discharge from the hospital is a powerful 
predictor of re-hospitalization and mortality[7, 45, 46].
Economic burden
  In 1 in 9 deaths in the United States, HF is  mentioned on the death certificate. The number of deaths 
with any mention of HF was as high in 2006 as it was in 1995[21]. Approximately 7% of all cardiovas-
cular deaths are due to HF. In 2012, HF costs in the United States exceeded $40 billion 12. This  total 
includes the cost of healthcare services, medications, and lost productivity. The mean cost of HF-
related hospitalizations was $23,077 per patient and was higher when HF was a secondary rather 
than the primary diagnosis[7]. 
3.3 Etiology and pathophysiology
    Although many conditions can lead to HF (coronary artery disease, hypertension, cardiomyo-
pathies, valvular and congenital heart disease, arrhythmias, pericardial disease, myocarditis, pulmo-
nary hypertension, and cardiotoxic substances— including alcohol), the predominant cause of HF in 
the western world is ischemic heart disease[8].
a) Etiology
  Coronary artery disease notably increases the probability of developing HF; in 7–8  years after 
myocardial infarction up to 36% of patients will experience HF, especially those with left ventricular 
systolic dysfunction documented during admission[47].
   Hypertension  (systolic blood pressure over 140 mmHg, or diastolic blood pressure over 90 mmHg, 
or treatment with antihypertensive medication) may be the single most important modifiable risk factor 
for HF in the United States. Hypertensive men and women have a substantially greater risk for devel-
oping HF than normotensive men and women[7]. Elevated levels of diastolic and especially systolic 
blood pressure are major risk factors for the development of HF[7, 48]. The incidence of HF is greater 
with higher levels of blood pressure, older age, and longer duration of hypertension. Long-term treat-
ment of both systolic and diastolic hypertension reduces the risk of HF by approximately 50% [49]. 
  Obesity (body mass index over 30 kg/m2) and insulin resistance are important risk factors for the 
development of HF [50]. The presence of clinical diabetes markedly increases the likelihood of devel-
oping HF in patients without structural heart disease[51] and adversely affects the outcomes of pa-
tients with established HF [52]. 
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   Patients with known atherosclerotic disease (e.g., of the coronary, cerebral, or peripheral blood 
vessels) are likely to develop HF, and clinicians should seek to control vascular risk factors in such pa-
tients according to guidelines[7]. 
  Valvular abnormalities, factors indicative of heart disease (left ventricular hypertrophy, left ventricu-
lar dilatation), a familly history of HF, other conventional risk factors  (such as smoking), as well extra-
cardiac conditions (renal dysfunction, obstructive pulmonary disease) all increase the risk of HF[8].
b) Pathophisiology
  HF-REF is the best understood type of HF in terms of pathophysiology(Fig.3). The syndrome of HF 
arises as a consequence of an abnormality in cardiac structure, function, rhythm, or conduction[6]. HF 
may be viewed as a progressive disorder that is initiated after an index event either damages the heart 
muscle, with a resultant loss of functioning cardiac myocytes, or disruption of the ability of the myo-
cardium to generate force, thereby preventing the heart from contracting normally[11]. The index 
event may have an abrupt onset, as in the case of a myocardial infarction; it may have a gradual or 
insidious onset, as in the case of hemodynamic pressure or volume overloading; or it may be heredi-
tary, as in the case of many of the genetic cardiomyopathies. Regardless of the nature of the inciting 
event, the feature that is common to each of these index events is that they all, in some manner, pro-
duce a decline in pumping capacity of the heart. In most instances, patients will remain asymptomatic 
or minimally symptomatic after the initial decline in pumping capacity of the heart or will develop 
symptoms only after the dysfunction has been present for some time[11].
Fig. 3 – Pathophysiologic mechanisms of response to heart damage: compensatory mechanisms that become maladaptive responses. 
(Source: Bonow RO, et al. Branwald’s Heart Disease: a textbook of cardiovascular medicine. 9th edition. 2012).
  In response, hemodynamic and neuro-hormonal mechanisms are activated to preserve cardiac func-
tion. The decreased capacity of the left ventricle to empty during systole increases diastolic wall ten-
sion in non-injured pats of the heart. The left ventricle responds by enhancing its  contraction, following 
the Frank-Starling curve. Aditionally, the sympathetic nervous system is  activated, resulting in decrea-
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ses inotropism and chronotropism[11]. Both compensatory mechanisms also lead to increase in in-
ternal wall stress during diastole. In response, synthesis  of myofibrillar proteins is stimulated, resulting 
in increased wall thickness and a subsequent reduction of ventricular wall stress and dilatation, which 
reduces energy expenditure. An increase in diastolic wall stress in the atria suppresses the sympathe-
tic nervous system and leads to the release of atrial natriuretic peptide. In addition, B-type natriuretic 
peptide (BNP) and C-type natriuretic peptide are released, respectively, by the ventricular myocardium 
in response to elevations of end-diastolic pressure and volume, and by endothelial cells in response to 
shear stress. The natriuretic peptides improve the loading conditions on the heart through their diu-
retic, natriuretic and vasodilator properties. In this way, a hemodynamic balance is  achieved, which 
restores cardiac function. Long-term activation of these mechanisms, however, diminishes their fa-
vourable physiological effects and results in progressive deterioration of ventricular function. As car-
diac output declines, systemic perfusion is maintained by peripheral vasoconstriction and sodium re-
tention. Catecholamines, angiotensin II and vasopressin act to increase systemic blood pressure and 
expand intravascular volume, while prostaglandins and natriuretic peptides limit the pressor, antinatri-
uretic and antidiuretic effects of these vasoconstrictor systems. Water and salt retention result mainly 
from direct and indirect effects of the renin-angiotensin system on glomerular and tubular function.
  Although the precise reason that patients with left ventricular dysfunction remain asymptomatic is 
not certain, one potential explanation is that a number of compensatory mechanisms become activa-
ted in the setting of cardiac injury or depressed cardiac output; these appear to modulate left ventri-
cular function within a physiologic-homeostatic range, such that the functional capacity of the patient 
is preserved or is depressed only minimally. However, as patients transition to symptomatic HF, the 
sustained activation of neurohormonal and cytokine systems leads to a series  of end-organ changes 
within the myocardium referred to collectively as left ventricule remodeling that is sufficient to lead to 
disease progression in HF independent of the neurohormonal status of the patient[11]. What charac-
terizes untreated systolic dysfunction is progressive worsening of these changes over time, with in-
creasing enlargement of the left ventricule and decline in EF, even though the patient may be asymp-
tomatic initially[5].
  The progression of left ventricular systolic dysfunction and HF syndrome, owing to “remodelling” (as 
a result of loss of myocytes and maladaptive changes in the surviving myocytes and extracellular 
matrix), probably occurs  in two main ways[6]. One is as a consequence of intercurrent cardiac events 
(e.g., myocardial infarction), and the other as a consequence of the systemic processes activated 
because systolic function is reduced (e.g., neurohumoral pathways)[6].
b.1) Neurohormonal model
  A growing body of experimental and clinical evidence suggests that HF progresses as a result of the 
overexpression of biologically active molecules that are capable of exerting deleterious effects on the 
heart and circulation[53]. Two key neurohormonal systems activated in HF are sympathetic nervous 
system (SNS) and the renin-angiotensin-aldosterone system (RAAS)[5] which are responsible for 
maintaining cardiac output through increased retention of salt and water, peripheral arterial 
vasoconstriction, and increased contractility, and for activation of inflammatory mediators, which 
are responsible for cardiac repair and remodeling. 
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- Sympathetic nervous system (SNS)
  The activation of the SNS is one of the most important mechanisms and occurs early in the course 
of HF. Activation of the SNS in HF is accompanied by a concomitant withdrawal of parasympathetic 
tone. Although these disturbances in autonomic control were initially attributed to loss of the inhibitory 
input from arterial or cardiopulmonary baroreceptor reflexes, there is increasing evidence that 
excitatory reflexes may also participate in the autonomic imbalance that occurs in HF[11, 54] (Fig. 4). 
Fig. 4 – Neurohormonal model: sympathetic nervous system. (Source: Bonow RO, et al. Branwald’s Heart Disease: a textbook of car-
diovascular medicine. 9th edition. 2012).
  Under normal conditions, inhibitory inputs from the high-pressure carotid sinus and aortic arch 
baroreceptors and the low-pressure cardiopulmonary mechanoreceptors are the principal inhibitors of 
sympathetic outflow, whereas discharge from the nonbaroreflex peripheral chemoreceptors and 
muscle metaboreceptors are the major excitatory inputs to sympathetic outflow. The vagal limb of the 
baroreceptor heart rate reflex is also responsive to arterial baroreceptor afferent inhibitory input. 
Healthy individuals display low sympathetic discharge at rest and have high heart rate variability. 
However, in HF patients, inhibitory input from baroreceptors and mechanoreceptors decreases and 
excitatory input increases, with the net result that there is a generalized increase in sympathetic nerve 
traffic and blunted parasympathetic nerve traffic, with a resultant loss of heart rate variability and 
increased peripheral vascular resistance[11, 54].
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  As a result of the increase in sympathetic tone, there is an increase in circulating levels of 
norepinephrine, a potent adrenergic neurotransmitter. The elevation of the levels of circulating 
norepinephrine result from a combination of increased release with reduced uptake. In patients with 
advanced HF, the circulating levels of norepinephrine in resting patients are two to three times those 
found in normal subjects. Indeed, plasma levels of norepinephrine may predict mortality in patients 
with HF. Whereas the normal heart usually extracts norepinephrine from the arterial blood, in patients 
with moderate HF, the coronary sinus norepinephrine concentration exceeds the arterial 
concentration, indicating increased adrenergic stimulation of the heart. However, as HF progresses, 
there is a significant decrease in the myocardial concentration of norepinephrine [11].
    Increased sympathetic activation of the beta1-adrenergic receptor results in increased heart rate 
and force of myocardial contraction, with a resultant increase in cardiac output. In addition, the 
heightened activity of the adrenergic nervous system leads to stimulation of myocardial alpha1-
adrenergic receptors, which elicits a modest positive inotropic effect, as well as peripheral arterial 
vasoconstriction. Although norepinephrine enhances both contraction and relaxation and maintains 
blood pressure, myocardial energy requirements are higher, which can intensify ischemia when 
myocardial oxygen delivery is restricted. The higher adrenergic outflow from the central nervous 
system may also trigger ventricular tachycardia or even sudden cardiac death, particularly in the 
presence of myocardial ischemia. Thus, activation of the sympathetic nervous system provides short-
term support that has the potential to become maladaptive in the long term[11].
- Renin-angiotensin-aldosterone system (RAAS)
  The components of the RAAS are activated comparatively later in HF. The presumptive mechanisms 
for RAAS activation in HF include renal hypoperfusion; decreased filtered sodium reaching the 
macula densa in the distal tubule; and increased sympathetic stimulation of the kidney, leading 
to increased renin release from the juxtaglomerular apparatus[11] (Fig. 5).
  Renin cleaves four amino acids from circulating angiotensinogen, which is synthesized in the liver, to 
form the biologically inactive decapeptide angiotensin I. Angiotensin-converting enzyme (ACE) cleaves 
two amino acids from angiotensin I to form the biologically active octapeptide (1-8) angiotensin II. The 
majority (∼90%) of ACE activity in the body is found in tissues; the remaining 10% of ACE activity is 
found in a soluble (non–membrane bound) form in the interstitium of the heart and vessel wall. The 
importance of tissue ACE activity in HF is suggested by the observation that ACE mRNA, ACE binding 
sites, and ACE activity are increased in explanted human hearts. Angiotensin II can also be 
synthesized through renin-independent pathways, through the enzymatic conversion of 
angiotensinogen to angiotensin I by kallikrein and cathepsin G and through the activation of 
chymase[11].
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Fig. 5 – Neurohormonal model: renin-aldosterone-angiotensin system. (Source: Bonow RO, et al. Branwald’s Heart Disease: a textbook 
of cardiovascular medicine. 9th edition. 2012).
  Other neurohormonal pathways or neurohormones potentially involved in myocardial damage are 
oxidative stress, arginine vasopressin, natriuretic peptides, endothelin, neuropeptide Y, urotensin II, 
nitric oxide, bradykinin, adrenomodullin, apelin, adipokines and inflammatory mediators[11]. 
The important unifying concept that arises from the neurohormonal model is  that the 
overexpression of biologically active molecules contributes to disease progression by virtue of 
the deleterious effects these molecules exert on the heart and circulation[11]. In addition to 
causing further myocardial injury, these systemic responses have detrimental effects on the blood 
vessels, kidneys, muscles, bone marrow, lungs, and liver, and create a pathophysiological ‘vicious 
cycle’, accounting for many of the clinical features of the HF syndrome, including myocardial electrical 
instability. Interruption of these two key processes is the basis of much of the effective treatment of 
HF[5]. The molecular, structural, and functional changes in the heart combined with these systemic 
processes, coupled with electrolyte imbalances, result in electrical as well as mechanical dysfunction 
of the heart[6, 55, 56]. 
b. 2) Left ventricular remodeling
    Although the neurohormonal model explains many aspects of disease progression in the failing 
heart, there is  increasing clinical evidence to suggest that our current neurohormonal models fail to 
completely explain disease progression in HF. That is, whereas neurohormonal antagonists stabilize 
HF and in some cases reverse certain aspects of the disease process, HF will progress in the 
overwhelming majority of patients, albeit at a slower rate. It has recently been suggested that the 
process of left ventricular remodeling is directly related to future deterioration in left ventricular 
performance and a less favorable clinical course in patients with HF[57]. Whereas the complex 
changes that occur in the heart during LV remodeling have traditionally been described in anatomic 
terms, the process of LV remodeling also importantly affects the biology of the cardiac myocyte, the 
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volume of myocyte and nonmyocyte components of the myocardium, and the geometry and 
architecture of the LV chamber[11].
3.4 Comorbidities
  Together with the key pathophysiological processes in HF – left ventricular remodelling and activa-
tion of neurohormonal pathways—and age, comorbidity is among the main determinants of progno-
sis[6]. Many patients with HF have comorbidity related to the underlying cardiac problem or its cause 
(e.g., angina, hypertension, diabetes, smoking-related lung disease) and age (e.g., osteoarthritis), as 
well as a consequence of HF (e.g., arrhythmias) and its treatment (e.g., gout from diuretics)[44]. Some 
common comorbidities have many causes (e.g., renal dysfunction), whereas others are not fully ex-
plained (e.g., anemia, depression, disorders of breathing, and cachexia)[58-60]. The existence of 
many comorbidities creates the potential for drug intolerance and drug interactions and makes the 
management of HF very complex[44]. As more patients with HF survive longer and progress to more 
advanced stages, renal failure is becoming one of the most common and difficult to manage comor-
bidities[6].
  As a common disease in the elderly, HF should not be viewed in isolation: anemia, cachexia, renal 
impairment, obstructive sleep apnea, COPD and diabetes mellitus are conditions frequently observed 
in HF patients and unfavorably affect prognosis[8, 61] (Fig. 6). The most prevalent conditions in HF 
patients are renal failure, described as cardio-renal syndrome (about 40%)[62], anemia (37%)[63], 
COPD (20-30%)[64] and depression (15-36%)[65]. Comorbidity was found to be one of the prime de-
terminants of prognosis in a study of patients admitted with HF and contributes to the poor quality of 
life as perceived by HF patients[8, 61]. The complex interplay between diseases previously perceived 
as entities on their own is increasingly acknowledged[8, 61]. According to some population studies, 
more than one half of all hospitalizations were related to non-cardiovascular[21, 27].
  Chronic kidney disease is common in patients with HF and coronary artery disease, and these 
patients have more advanced coronary atherosclerosis. Patients with renal insufficiency are less likely 
to be prescribed efficacious therapies, but have better outcomes if they receive these medica-
tions[62]. The term ‘cardio-renal syndrome’ refers to the complex interrelation between heart and kid-
neys, and denotes the decline of renal function in the setting of CHF. It originates from the observation 
that even minor alterations in renal function, as evidenced by reduced glomerular filtration rate and 
microalbuminuria, represent potent cardiovascular risk factors[64].
  Anemia is a common finding in patients with chronic HF with prevalence rates between 20% and 
50%. The incidence increases with NYHA functional class. It is  a strong independent predictor of im-
paired survival: in a large study of >150,000 patients, the mortality risk was doubled in anemic HF pa-
tients[62, 66]. Also, is associated with increased morbidity and hospitalization rates. Anemia is variably 
reported, in part due to the lack of consensus on the definition of anemia. Anemia is also more com-
mon in women,  is seen in both patients  with HF-REF and HF-PE and is associated with reduced ex-
ercise capacity, impaired health related quality of life (HRQOL), and a higher risk for hospitalization[62, 
66].
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Fig. 6 – Comorbidity and its implications in heart failure: causation, exacerbation, impact in seeking care, in low adherence and masking of 
symptoms (Source: Angermann CE. European Journal of Heart Failure Supplements, 2009. 8(Supplement 1): p. i5-i10.[60])
  Chronic obstructive pulmonary disease (COPD) is frequent in patients with CHF, with a preva-
lence ranging from 20% to 30%. Since the coexistence of both conditions has important therapeutic 
implications, early recognition is critical. However, COPD may be missed in patients with CHF, be-
cause dyspnea is erroneously attributed to CHF, and vice versa. Measurement of plasma natriuretic 
peptide levels may be useful to uncover unsuspected CHF in COPD patients. Also, HF appears to be 
frequently present in patients with COPD[8]. However, accurate and precise data on the prevalence of 
COPD in patients with HF are still lacking, and prognosis of patients  with HF with concomitant COPD 
is largely unknown. Patients with concurrent HF and COPD may have therapeutic constraints that 
have not been comprehensively investigated[67].
  Depression is common in patients with HF; those with depressive symptoms have lower HRQOL, 
poorer self-care, worse clinical outcomes, and more use of healthcare services[68]. Although it is fre-
quently assumed that depression occurs only among hospitalized patients, a multicenter study dem-
onstrated that even at least 3  months after a hospitalization, 63% of patients with HF reported symp-
toms of depression[69]. The mechanism remains unclear[69, 70]. Although remission from depression 
may improve cardiovascular outcomes, the most effective intervention strategy is not yet known[68]. 
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
  Patients  with HF are more likely than the general population to develop atrial fibrillation (AF). There 
is a direct relationship between the NYHA class and prevalence of AF in patients with HF progressing 
from 4% in those who are NYHA class I to 40% in those who are NYHA class IV. AF is  also a strong 
independent risk factor for subsequent development of HF. In addition to those with HF-REF, patients 
with HF-PEF are also at greater risk for AF. AF can worsen symptoms in patients with HF, and, con-
versely, worsened HF can promote a rapid ventricular response in AF[7].
3.5 Diagnosis
  HF can present suddenly, as the consequence of an acute cardiac event such as myocardial infarc-
tion; chronically, in most cases in the community to a primary-care physician, or in an acute-on-
chronic fashion, when a period of worsening symptoms and signs is followed by an emergency pres-
entation with decompensation.
Symptoms and signs
  The diagnosis of HF can be difficult, especially in the early stages. The symptoms may be due to 
other problems, such as chronic lung disease, anemia, venous insufficiency, renal dysfunction, and 
hypothyroidism, or concomitant treatments, such as calcium-channel blockers or glitazones[71-73]. 
Symptoms that are more specific (orthopnea and paroxysmal nocturnal dyspnea) are less common, 
especially in patients with milder symptoms, and are, therefore, insensitive[5]. Other signs, such as 
raised jugular-venous pressure, cardiomegaly, and a third heart sound, are more specific but much 
less common and harder to detect[71-73]. Even if HF is correctly diagnosed on the basis of symp-
toms and signs, differentiation between preserved and reduced left-ventricular systolic function is still 
difficult. Consequently, the diagnosis of HF requires investigation[6]. 
Initial investigation
  The key investigations are: echocardiography to demonstrate structural heart disease; electrocardi-
ography (ECG) to show rhythm, rate, and conduction; chest radiography to exclude primary pulmo-
nary disease and identify edema; blood chemistry; and hematology (Fig. 7). As well as providing diag-
nostic information, each investigation helps to guide treatment[5, 6]. Routine biochemical and hema-
tological investigations are also important, partly to determine whether RAAS blockade can be initi-
ated safely (renal function and potassium), to exclude anemia (which can mimic or aggravate HF) and 
other useful information[5, 6].
Natriuretic peptides
  Measurement of the blood concentration of natriuretic peptides secreted by the heart can help in the 
diagnosis  of HF especially in the acute setting[5, 6]. B-type natriuretic peptide (BNP) and N-terminal 
pro-BNP are more useful than the A-type natriuretic peptides[5]. Also, BNP is  a well-established prog-
nostic indicator in HF patients with a wide range of functional impairment[74]. 
  Because the signs and symptoms of HF are so non-specific, many patients with suspected HF re-
ferred for echocardiography are not found to have an important cardiac abnormality[5, 6]. Where the 
availability of echocardiography is limited, an alternative approach to diagnosis is  to measure the 
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blood concentration of a natriuretic peptide, hormones secreted in increased amounts when the heart 
is diseased or the load on any chamber is increased (e.g. by AF, pulmonary embolism, and some non-
cardiovascular conditions, including renal failure)[5, 6]. Natriuretic peptide levels also increase with 
age, but may be reduced in obese patients. A normal natriuretic peptide level in an untreated patient 
virtually excludes significant cardiac disease[5, 6]. 
  For patients presenting with acute onset or worsening of symptoms, the optimal exclusion cut-off 
point is 300 pg/mL for NT-proBNP and 100 pg/mL for BNP[5, 6]. For patients presenting in a non-
acute way, the optimum exclusion cut-off point is 125 pg/mL for NT-proBNP and 35 pg/mL for BNP. 
The sensitivity and specificity of BNP and NT-proBNP for the diagnosis  of HF are lower in non-acute 
patients[5, 6, 75-77]. 
Other investigations
  Other tests are generally only required if the diagnosis remains unclear (e.g. if echocardiographic im-
ages are suboptimal or if an unusual cardiac cause, or a non-cardiac cause, of the patient’s  condition 
is suspected) or if further evaluation of the underlying cause of the patient’s cardiac problem is indi-
cated (e.g. perfusion imaging or angiography in suspected coronary artery disease or endomyocardial 
biopsy in certain infiltrating diseases of the myocardium)[5, 6].
Fig. 7 – Algorithm for acute and non-acute heart failure diagnosis. (Source: McMurray JJ, et al. Eur Heart J, 2012. 33(14): p. 
1787-847.[5]).
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Algorithm
  In patients presenting to hospital as an emergency with suspected HF and acute onset of symp-
toms, early echocardiography is recommended (and immediate echocardiography in shocked or se-
verely hemodynamically compromised patients) (Fig. 7). If a natriuretic peptide is  measured, a high 
exclusion cut-off point should be used. In patients presenting non-emergently in primary care, or to a 
hospital outpatient clinic, with slow onset of symptoms (and signs) suggestive of HF, an ECG and na-
triuretic peptide measurement may be used as a means of identifying patients who most need echo-
cardiography (an echocardiogram is indicated if the natriuretic peptide level is above the exclusion 
threshold/ECG is abnormal). In these patients, a lower exclusion natriuretic peptide cut-off point 
should be used to prevent a ‘false-negative’ diagnosis of HF. Patients with a high pre-test likelihood of 
HF, such as those with a history of myocardial infarction, may be referred directly for echocardiogra-
phy.
3.6 Prognosis
  Prognosis means foreseeing, predicting, or estimating the probability or risk of future conditions. In 
medicine, prognosis commonly relates to the probability or risk of an individual developing a particular 
state of health (an outcome) over a specific time, based on his  or her clinical and non-clinical 
profile[78]. Outcomes are often specific events, such as death or complications, but they may also be 
quantities, such as disease progression, (changes in) pain, or quality of life[78]. 
  As a leading cause of death worldwide, predicting the progression of HF is important from the 
perspectives of facilitating patient and physician understanding of disease course and of determining 
the appropriate timing of the increasing number of medications and invasive interventions available to 
the advanced HF patient[79]. 
  The prognosis of HF patients remains poor, even with the development of effective pharmacological 
and non-pharmacological interventions[8]. Although information on the natural history of a disease is 
relevant to illustrate its burden for health care and the society at large, prognostication in individual 
patients plays a crucial role in daily clinical practice[8]. After the diagnosis (and possible etiology) of HF 
has been established, estimation on individual patient’s probability of developing clinically relevant 
prognostic outcomes may be done—for example, a 5-year survival probability. Such estimates are 
typically based on patients’ characteristics, including age, comorbidity, severity and cause of HF that 
are known to influence prognosis. This information, together with the anticipated, preferably evidence-
based, effect of possible therapeutic interventions and patient preferences, is instrumental in the deci-
sion which therapeutic measures should be taken. Importantly, this implies precise enough predictions 
of the future—a difficult task, the more since, apart from survival, other prognostic outcomes are of 
interest in HF, including hospitalizations and quality of life. The recent development of prognostic 
scores, enabling physicians to estimate an individual’s probability of developing relevant complications 
as a function of the level of a limited number of prognostic factors, may be helpful.
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Outcomes
  The most commonly studied outcomes in HF are death and/or hospitalization. For both of these, the 
direct cause is often specified, e.g. due to HF, cardiovascular-related cause, or all-cause death and/or 
hospitalization are considered. In HF studies all-cause death/hospitalization is  preferred over disease-
specific cause because they do not depend on the exact ascertainment of the event’s cause and also 
there are commonly multiple comorbidities associated that closely interplay with cardiac dysfunction 
and may influence and be influenced by the failing heart.
Prognosis in HF
  Survival after HF diagnosis has improved over time, as shown by data from the Framingham Heart 
Study (FHS) [21, 80] and the Olmsted County Study (OCS) [21, 29]. 
  In FHS, mortality rate in men after 1 year of follow-up decreased from 30% in the period 1950-1969 
to 28% in the period 1990-1999, after 5 years from 70% to 59% during the same period. Similarly in 
women 1 and 5 years mortality rate declined from 28% to 24% and from 57% to 45% respectively, in 
the same period [21, 80]. 
  In OCS, survival after HF diagnosis was worse among men than women (RR 1.33; 95% CI, 
1.24-1.43) but overall improved over time (5-year age-adjusted survival, 43% in 1979-1984 vs 52% in 
1996-2000, p<0.001)[29]. Men and younger persons experienced larger survival gains, contrasting 
with less or no improvement for women and elderly persons. 
  In the elderly, data from Kaiser Permanente indicate that survival after the onset of HF has also im-
proved[21, 27]. In this  study, on 5-year follow-up and adjustment for age and comorbidities, the mor-
tality hazards decreased 33% (95% CI 14% to 48%) among men and 24% (95% CI 1% to 43%) 
among women[27]. However, the death rate remains high: within 1 year of follow up a third of patients 
die and 50% die within 5 years of diagnose[21, 29, 33].
Prognostic factors in HF
  Many variables provide prognostic information, although most of this can be obtained from readily 
available data such as age, etiology, NYHA class, EF, key co-morbidities (renal dysfunction, diabe-
tes, anemia, hyperuricemia), and plasma natriuretic peptide concentration[79, 81-85] (Table 1). 
Clearly these variables change over time, as does prognosis. Assessment of prognosis is particularly 
important when counselling patients about devices and surgery (including transplantation) and in 
planning end-of-life care with patients, their family, and caregivers[5, 61].
  It is noteworthy that in order to be of importance and serve practice, prognostic determinants need 
not be causally related to the prognostic outcome. Age and gender, for example, are important prog-
nostic markers in many diseases, even after adjustment for other prognostic determinants, although 
age per se may not be causally implicated, but indicates other, often immeasurable, factors that are 
etiologically involved[8]. Prognostic determinants in HF can be categorized in: patient characteristics 
and comorbidity; laboratory measurements; functional parameters and ventricular function; and inter-
ventions received[8].
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Table 1 – Prognostic variables in heart failure. (Source: McMurray JJ, et al. Eur Heart J, 2012. 33(14): p. 1787-847. [57]).
!
  In the general population, knowledge of age and sex can provide high accuracy in prediction of life 
expectancy. As progressively more severe HF develops, the predictive value of these factors declines, 
though female sex appears in multiple trials to be protective against HF mortality[79, 86, 87].
  Impaired socioeconomic status in adulthood and childhood has consistently been shown to be a 
predictor of worsened outcomes[51, 88]. The impact of ethnicity on HF mortality has been more con-
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
flicting, with studies showing increased rates of hospitalization, along with both survival advantage 
and detriment in black patients[79, 89] mainly because socioeconimic status is one of its 
determinants.
  Infiltrative and ischemic etiologies of HF are associated with worse prognosis, with one study 
showing 50% increased mortality for ischemic cardiomyopathy and 400% increased mortality for infil-
trative cardiomyopathy as compared with idiopathic cases[90].
  In the general population, increased systolic blood pressure (BP) and higher body mass index 
(BMI) are associated with worse outcomes and increased the risk of development of HF (approxi-
mately a 5% increase in risk for each 1-kg/m2 increase in BMI). However, once HF has developed, 
higher BP and BMI are associated with decreased risk[91]. This  may be due to lower BP serving as a 
marker of worsened HF and impaired forward flow. The state of cardiac cachexia is associated with 
significantly worsened prognosis, and multiple studies have shown improved survival in established 
HF patients with increased BMI, a trend that continues even into the early stages of morbid obesity. A 
10% reduction in mortality for each 5-unit increase in BMI was seen in a large registry of more than 
100,000 patient presentations for acute decompensated HF. The reverse epidemiology for weight 
has been noted in end-stage renal disease and metastatic cancer as well, raising the possibility of a 
chronic malnutrition-inflammation state heralded by these markers and associated with worsened 
outcomes[79, 92].
  Aside from baseline characteristics of a patient, interventions also have an effect on prognosis (β-
Blockers, ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists). On the con-
trary, high doses of diuretics are being correlated with worsened prognosis although the exact impli-
cations of diuretics on the prognosis its unknown[93]. Presence of positive inotropic medications has 
an unquestionably deleterious effect on long-term survival[79].
  Device placement also changes patient prognosis, with appropriately selected patients showing a 
25% to 30% relative reduction in all-cause mortality after placement of an ICD and nearly 80% of New 
York Heart Association (NYHA) class III and IV patients showing symptom improvement of at least 1 
NYHA class after placement of cardiac resynchronization therapy (CRT) or CRT with defibrillator (CRT-
D)[79, 94]. Recent clinical trials of CRT-D vs ICD in NYHA class II patients  with EF less than 30% have 
suggested that CRT-D reduces HF hospitalizations and mortality[95].
  Reduced left ventricular EF is the defining feature of systolic HF and has consistently been associ-
ated with adverse outcomes[96]. Many aspects of the echocardiogram correlate with mortality in HF, 
including LV end-systolic volume and stroke volume, mitral and tricuspid insufficiency, right ventricular 
systolic dysfunction, impaired peak early- (E) to late- (A) mitral diastolic flow ratios (E:A ratios), and im-
paired peak early-diastolic mitral filling velocity to peak early diastolic mitral annular velocity (E:E' ra-
tio)[96]. The CHARM trial showed that each 10% reduction in EF was associated with a 39% increase 
in the risk of mortality, but this was only for EF below 45%[97].      
  In HF-PEF improvements in mortality have been much less impressive than those in patients with 
HF-REF especially because comorbidities  such as diabetes and hypertension, associated with HF-
PEF, are increasing globally[79].
  The NYHA class has long been used as a simple, widely recognized metric of a patient's exercise 
capacity. Initiating one additional HF medicine has almost as favorable an effect on survival as reduc-
ing NYHA functional class by 1 category[79].
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  More quantitative methods of measurement include the 6-minute walk test. Having a patient walk on 
a treadmill using a modified Naughton protocol (1-metabolic equivalent increase in exertion with each 
2-minute increment in test stage) was shown in one study to associate with a 7%increased risk of 
death for each 1-minute reduction in exercise capacity[98].
  Impaired oxygen consumption with maximal exertion (peak VO2) correlates with worsened out-
comes and has been used as a criterion for evaluation of cardiac transplantation, with current trans-
plant candidates generally having a peak VO2 less than 12[99]. 
  Excessive activation of the sympathetic nervous system is an important component of the de-
velopment of HF. Elevated systemic catecholamine levels have been associated with worsening prog-
nosis in HF. Markers of cardiac chamber dilation, atrial natriuretic peptide, and BNP have shown high 
prognostic value in HF, with the longer half-life of BNP (23  minutes vs 3-5 minutes for atrial natriuretic 
peptide) and dominant expression of BNP in abnormal ventricular cells as potential explanations for its 
wider utility[74]. An analysis from Val-HeFT showed a HR of 2.06 for morbidity and mortality with an 
abnormal BNP, whereas a pooled review showed a 35% increase in relative risk of death for each 
100-pg/mL increment in baseline BNP. BNP has been shown to predict other important end points, 
including hospitalization risk in patients presenting to the emergency department and likelihood of re-
hospitalization based on predischarge value[100].
  Common markers of inflammation are associated with the risk of development of HF in the general 
population, and levels  of interleukin-6, C-reactive protein, and tumor necrosis factor α have been 
shown to correlate with worsened outcomes once heart failure has developed. Several proxy corre-
lates of inflammation and stress, such as a decreased lymphocyte count or elevated leukocyte count, 
elevated uric acid, low cholesterol, hypoalbuminemia, and anemia, are associated
with increased risk[79].
  Comorbidities are known to influence survival unfavourably in HF. In diabetes mellitus, diabetic pa-
tients on insulin, there was a doubling in risk (HR 2.03) compared with non-diabetics[84]. Anemia is 
present in approximately 25% of the HF, and each 1-g/dL reduction in hemoglobin has been associ-
ated with a 20% multivariate adjusted increase in risk of death[101]. In chronic renal failure, mortality 
worsens across the range of renal function, with 15% increased risk for every 0.5 mg/dl increase in 
creatinine and 7% increased risk for every 10 mL/min decrease in eGFR[51]. Patients with both HF 
and chronic renal failure have an extremely poor prognosis; this pathophysiological condition has been 
termed severe cardiorenal syndrome, in which combined cardiac and renal failure amplify progression 
of the individual organ pathology. In practice, not all these prognostic parameters will be known or 
even necessary[8]. The combination of a few independent prognostic variables may be sufficient to 
guide patient management. This does not imply that correction, if possible, of these prognostic de-
terminants improves survival[79]. 
3.7 Management of heart failure
  Major difficulties in studying HF result from its heterogeneous nature: right- vs left-sided, high vs low 
output, acute vs. chronic, systolic vs diastolic HF. Diastolic HF is  often an exclusion diagnosis[13] and 
little is known about optimal treatment strategies for this population. In contrast, comprehensive 
guidelines exist for the treatment of systolic HF, based on robust evidence[5].
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  The goals of treatment in patients with established HF are to relieve symptoms and signs, prevent 
hospital admission, and improve survival. Although the focus of clinical trials was previously mortality, 
it is  now recognized that preventing HF hospitalization is important for patients and healthcare sys-
tems[5, 102].  Reductions in mortality and hospital admission rates both reflect the ability of effective 
treatments to slow or prevent progressive worsening of HF. This is often accompanied by reverse LV 
remodeling and a reduction in circulating natriuretic peptide concentrations[5, 103, 104].
  From several non-randomized and randomized clinical studies it seems well documented that treat-
ment in specialized HF clinics reduces readmission frequencies and improve quality of care for HF pa-
tients[105,106].  Also, they show a reduced risk of hospital readmission and death, both in the short 
and long term, among patients  discharged from a hospitalization index to a HF clinic, as compared 
with those who were discharged to the outpatient care of their usual assistant physician[106]. Care 
providers should be encouraged to initiate HF management programs including elements of nurse 
intervention and to design the clinics to meet the local needs in the best, and most feasible, way it 
can [105,106].
3.1.7 Pharmacologic treatment of heart failure – the role of diuretic therapy
  The relief of symptoms, improvement in quality of life, and increase in functional capacity are also 
very important to patients, but they have not been the primary outcome in most trials[5, 105]. This is in 
part because they are difficult to measure and partly because some treatments previously shown to 
improve these outcomes also decreased survival. However, effective pharmacological therapies and 
cardiac CRT seem to improve these outcomes, as well as mortality and hospitalization[5].
  Three neurohormonal antagonists—an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB), a 
beta-blocker, and a mineralocorticoid receptor antagonist —are fundamentally important in modifying 
the course of systolic HF and should at least be considered in every patient. They are commonly used 
in conjunction with a diuretic given to relieve the symptoms and signs of congestion[5, 7] (Fig. 8). 
  HF-PEF is increasingly recognized as a major public health problem worldwide[16]. However, trials 
using comparable and efficacious agents for HF-REF have generally been disappointing in showing 
reduction of morbidity and mortality when applied to patients with HF-PEF[7]. Thus, most of the rec-
ommended therapies for HF-PEF are directed at symptoms, especially comorbidities, and risk factors 
that may worsen cardiovascular disease[5, 7]. Adequate treatment of hypertension (ACEi and/or ARB 
are often considered as first-line agents) and myocardial ischemia (coronary artery disease is common 
in patients with HF-PEF) is considered to be important, as is control of the ventricular rate in patients 
with atrial fibrillation[5, 7, 16].
a) Diuretics
    Diuretics, though not specific long-term prognostic modifiers, are cornerstone in the symptomatic 
management of HF[5, 7, 19, 67] as most of the symptoms of congestive HF result from excess extra-
cellular fluid volume (Fig. 8, 9).
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Fig. 8 – Pharmacologic treatment recommendations in heart failure with reduced ejection fraction. (Adapted from: Yancy CW, et al. J Am 
Coll Cardiol, 2013 OCT 15:62(16):e147-239[7]; McMurray JJ, et al. Eur Heart J, 2012. 33(14): p. 1787-847[5])
  The effects of diuretics on mortality and morbidity have not been studied in patients  with HF, unlike 
ACE inhibitors, beta-blockers, and mineralocorticoid antagonists because of recognized symptomatic 
benefits, a formal evaluation in randomized trials became impossible as they relieve dyspnea and 
edema[5, 7, 106-108] and are recommended for this reason in patients with signs and symptoms of 
congestion, irrespective of EF[5, 7]. However, the interpretation of symptoms and signs by patients 
and physicians is  highly variable. Among patients with confirmed symptomatic HF, symptoms are 
likely to reflect true congestion but, given the high prevalence of COPD and obesity, a non-negligible 
proportion of dyspnea can easily lead to excessive use of diuretics[5, 7, 19, 67].
  Loop diuretics produce a more intense and shorter diuresis than thiazides, which cause a more gen-
tle and prolonged diuresis. Thiazides may be less effective in patients with reduced kidney function. 
Loop diuretics are usually preferred to thiazides in HF-REF although they act synergistically and the 
combination may be used (usually on a temporary basis) to treat resistant edema[5, 7, 19, 67].
  The aim of using diuretics is to achieve and maintain euvolemia (the patient’s ‘dry weight’) with the 
lowest achievable dose. This means that the dose must be adjusted, particularly after restoration of 
dry body weight, to avoid the risk of dehydration leading to hypotension and renal dysfunction. This 
may reduce cardiac output in patients with HF-PEF and often needlessly prevents the use of (or 
achievement of the target dose of) other disease-modifying therapies such as ACE inhibitors  (or 
ARBs) and mineralocorticoid receptor antagonists in patients with HF-REF. Many patients can be 
trained to self-adjust their diuretic dose, based on monitoring of symptoms/signs of congestion and 
daily weight measurements[5, 7, 19, 67].
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a.1) Rationale for the treatment with diuretics in HF
  There is  considerable evidence to show that diuretics improve quality of life by providing relief from 
symptoms of HF[14, 109, 110] (Fig. 9). In the congested patient, diuretics lower filling pressures, re-
duce lung water content, and are the most efficacious drugs available to relieve symptoms rapidly. 
Symptomatically worse patients are likely to gain the greatest improvement in quality of life from diu-
retic treatment[109, 110]. Diuretics are more effective in improving symptoms when compared with 
ACE-inhibitors. The bioavailability of the diuretic used may also influence its effects on quality of 
life[109, 110]. Both bumetanide and torsemide, when taken orally, have a more consistent level of ab-
sorption when compared with furosemide. Torsemide is  associated with less fatigue in CHF patients 
when compared with furosemide[14, 109, 110].
!
Fig. 9 – Pharmacologic treatment algorithm for Heart Failure. (Source: McMurray JJ, et al. Eur Heart J, 2012. 33(14): p. 1787-847[5]).
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  Withdrawal of diuretics in stable compensated patients with CHF has been shown in several studies 
to result in symptoms of congestion[109]. When diuretic treatment was discontinued in 41 patients 
with a history of HF, it was found that diuretics had to be restarted in 71% of patients after a median 
of 15 days, owing to worsening HF symptoms[109]. A history of hypertension, baseline furosemide 
dose of 40 mg/day, and a LVEF (27%) were independent predictors of diuretic re-initiation[109]. 
  With the exception of aldosterone antagonists, diuretics have not been studied in large-scale HF 
mortality endpoint trials and this remains the major cause for uncertainty regarding their use in day-
to-day clinical practice. In the meta-analysis of randomized controlled trials assessing the role of diu-
retics in HF, only three small placebo-controlled studies (202 participants) had reported on the effect of 
diuretic therapy on mortality[93, 109, 111, 112]. The most recent meta-analysis[93] included 14 trials 
(525 participants), 7 placebo-controlled and 7 compared diuretics against other agents such as ACE 
inhibitors or digoxin. Mortality was lower for participants treated with diuretics than with placebo, 
odds ratio (OR) for death 0.24, 95% confidence interval (CI) 0.07 to 0.83; p = 0.02. In patients with 
CHF, treatment with diuretic therapy produced a relative reduction in mortality of about 70% (absolute 
reduction of 8%), with wide confidence intervals, compared to placebo. If this estimate is correct, 
about 80 deaths could be avoided for every 1000 patients treated. However, this evidence was based 
on only 15 deaths out of 221 participants (6.8%). Admission for worsening HF was reduced in those 
taking diuretics in two trials (169 participants), OR 0.07 (95% CI 0.01 to 0.52; p= 0.01). Diuretic ther-
apy compared to placebo produced a similar reduction (8% absolute risk reduction) in the risk of 
worsening HF. In four trials (91 participants), diuretics improved exercise capacity in participants with 
CHF with difference in means walking meters distance (WMD) - 0.72, 95% CI 0.40 to 1.04; p<0.0001. 
Diuretics significantly increased exercise capacity by about 28% to 33%. Importantly, the mean age of 
the patients in the studies was 59 years, considerably lower than the mean age of HF patients in the 
population, which is about 74 years. The proportion of women was higher in these trials than in other 
trials in HF[93]. 
  As yet diuretic drugs have not been shown to retard the clinical deterioration or improve prognosis in 
patients with CHF, because adequately sized trials to address these questions have not been carried 
out. The common clinical impression is that diuretics do reduce mortality and retard progression of 
HF[93].
  This evidence is not sufficient by current standards to justify widespread use of diuretics to influence 
clinical outcomes in CHF since diuretics were introduced without the backing of large RCTs that 
would now be considered essential[93]. In fact, some studies suggest that in patients with advanced 
systolic HF, the use of higher doses of loop diuretics is associated with significantly increased all-
cause mortality: higher diuretic doses (≥160 mg) were associated with a significant increase in 1- and 
2-year all cause mortality compared with the lowest loop diuretic doses (0 to 40 mg)[113]. 
  Although it may appear obvious that patients with HF requiring higher loop diuretic doses to prevent 
fluid retention and control symptoms might be sicker than patients receiving lower doses, the power-
ful and independent association with mortality warrants further consideration[113]. The activation of 
RAAS, the decrease in the glomerular filtration rate, the cardiorenal syndrome and the risk of sudden 
death by arrhythmias are some of the reasons pointed[113].
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  The implications for clinical practice are that a common, simple treatment is being used without clear 
evidence of major benefit on important clinical outcomes. It is important to acknowledge this fact and 
also to stimulate interest in further clinical trials that may help us to understand both how to optimize 
diuretic use and to understand more about their benefits[93].
a.2) Hemodynamic and neuroendocrine effects of diuretics
  The acute hemodynamic actions of diuretics reflect immediate direct or indirect vascular actions and 
those of diuresis and volume redistribution. Hemodynamic responses to diuretics are variable and de-
pendent on which diuretic is used, whether the patient has acute pulmonary edema or chronic com-
pensated HF, the degree of baseline neurohormonal activation, and presence of concomitant medica-
tions, such as ACE inhibitors[109, 114]. 
  In congested patients (e.g. acute pulmonary edema), intravenous administration of furosemide re-
sults in a rapid fall in right heart filling pressures and in an improvement in symptoms before any diure-
sis ensues[109, 114, 115]. However, in non-congested patients, there is  a predominant detrimental 
arteriolar vasoconstriction. With progressive diuresis, filling pressures continue to decline over time, 
whereas vascular resistance and stroke volume index tend to return to baseline. These initial adverse 
hemodynamic changes temporally correlate with increases in plasma norepinephrine and renin activi-
ty[116].
  After diuretic withdrawal, patients on ACE-inhibitor and a beta-blocker had clinically stability over 
the preceding 3  months. Diuretic withdrawal caused significant deterioration of hemodynamic pa-
rameters and worsening of chronic HF. The fact that the patients deteriorated is evidence supporting 
the notion that diuretics are needed for chronic therapy. It is possible, however, that if the patients had 
strictly restricted their sodium intake, they could have avoided the observed deterioration[117].
  The activation of RAAS associated with diuretic use may be a reno-protective mechanism to pre-
serve renal function in the setting of volume depletion and reduced renal blood flow[118]. Furosemide 
increases circulating levels of products of the RAAS by directly causing renin release from the macula 
densa and as a response to intravascular volume depletion[119]. Activation of the RAAS is associated 
with the progression of HF[120]. Subjects with symptomatic HF have elevated aldosterone levels, 
which is prognostically significant in this patient population[116]. The inhibition of aldosterone with spi-
ronolactone has been shown to reduce morbidity and mortality in patients with NYHA class II-IV HF[5, 
7, 121] possibly by favorable effects on heart rate variability and cardiac adrenergic tone, a reduction 
in cardiac fibrosis, and significant improvement in prognosis. 
  In non-congested  patients, intravenous bolus of furosemide did not change plasma renin and al-
dosterone concentrations. Continued oral furosemide results in a significant increases in plasma renin 
and aldosterone levels, suggesting late activation of the neurohumoral axis; alternatively or in addi-
tion, it may represent a reaction to overdiuresis. Prolonged activation of the RAAS may lead to pro-
gressive salt/water retention and peripheral vasoconstriction. The noxious effects of diuretics on the 
neuroendocrine system, may hence persist despite ACE-inhibitor therapy and may affect prognosis 
adversely[109].
  Volume depletion with subsequent hypotension, decreased cardiac output, and worsening renal 
function are common adverse effects of aggressive diuretic therapy. Electrolyte depletion, especially 
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hypokalemia and hypomagnesemia, can lead to arrhythmias. Hypocalcemia can lead to secondary 
hypoparathyroidism. Hyperuricemia associated with aggressive diuresis can lead to acute gouty 
flares. In addition, diuretic therapy, especially with loop diuretics, causes adverse neurohormonal ac-
tivation. The potassium-sparing diuretic may lead to hyperkalemia and worsening renal failure[5, 7, 
106, 109].
  Diuretics should be prescribed to all patients  who have evidence of, and to most patients with a prior 
history of, fluid retention. Diuretics should generally be combined with an ACE inhibitor, BB  and MRA. 
Few patients with HF will be able to maintain target weight without the use of diuretics[109].
a.3) Use of diuretics
  The most commonly used loop diuretic for the treatment of HF is furosemide, but some patients re-
spond more favorably to other agents in this category (e.g., bumetanide, torsemide) because of their 
increased oral bioavailability[7] (Table 2). 
Table 2 – Practical guidance on the use of diuretics in patients with heart failure. (Source: McMurray JJ, et al. Eur Heart J, 2012. 33(14): p. 
1787-847. [57]).
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  In outpatients with HF, diuretic therapy is commonly initiated with low doses, and the dose is in-
creased until urine output increases and weight decreases, generally by 0.5 to 1.0 kg daily. Further 
increases in the dose or frequency (i.e., twice-daily dosing) of diuretic administration may be required 
to maintain an active diuresis and sustain weight loss. The ultimate goal of diuretic treatment is to 
eliminate clinical evidence of fluid retention.
  Diuretics are generally combined with moderate dietary sodium restriction. Once fluid retention has 
resolved, treatment with the diuretic should be maintained in some patients to prevent the recurrence 
of volume overload. Patients are commonly prescribed a fixed dose of diuretic, but the dose of these 
drugs frequently may need adjustment. Patients may become unresponsive to high doses of diuretic 
drugs if they consume large amounts of dietary sodium, are taking agents that can block the effects 
of diuretics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], including cyclo-oxygenase-2 
inhibitors)[122-124] or have a significant impairment of renal function or perfusion[7].
a.4) Diurectic resistance
  A common problem with loop diuretics is  diuretic resistance. This occurs through various mecha-
nisms, the most important of which involves specific drug pharmacokinetics and physiologic adapta-
tions within the nephron. There are two different forms of adaptive diuretic resistance. First is the 
braking phenomenon. Immediately following the first dose of a loop diuretic, there is a diminished 
response to subsequent doses. The mechanisms leading to braking have not been fully determined. 
Loop diuretics directly stimulate renin secretion from the macula densa. In addition, diuretic-induced 
volume loss increases the filtration fraction and stimulates efferent sympathetic nerves, which leads to 
enhanced NaCl reabsorption through a variety of mechanisms[5, 7, 106-108]. The second type of 
adaptive resistance involves longer-term use of loop diuretics. In long-term diuretic therapy, there is 
increased delivery of solute distal to the loop of Henle. This results in hyperplasia and hypertrophy of 
the thiazide-sensitive cells  in the distal convoluted tubule and subsequent increase in distal sodium 
reabsorption[5, 7, 106-108].
  A good measure of diuretic resistance is a low fractional excretion of sodium in patients on chronic 
loop diuretics[125]. Post-diuretic sodium rebound is particularly problematic in patients who do not 
adequately restrict dietary sodium. These patients may have adequate natriuresis but inadequate diu-
resis[108]. A way to overcome this rebound phenomenon in patients with ADHF, apart from escalat-
ing doses, is to give the loop diuretic as a continuous infusion instead of a bolus. A meta-analysis of 
seven randomized controlled trials comparing efficacy of continuous versus bolus intravenous infusion 
of furosemide found greater urine output (measured as milliliters per 24 hours) in patients given fu-
rosemide by continuous infusion[106, 126]. However, the DOSE study[127] failed to show significant 
differences in patients’ global assessment of symptoms or in the change in renal function when diu-
retic therapy was administered by bolus as compared with continuous infusion or at a high dose as 
compared with a low dose (Fig. 10). Furthermore, meta-analysis of the existing limited studies did not 
confirm any significant differences in the safety and efficacy with continuous administration of loop 
diuretic, compared with bolus injection in patients with acute decompensated HF[11].
     The rebound effect from chronic loop diuretics results in up-regulation of thiazide-sensitive recep-
tors in the nephron. These cells also exhibit increased transcellular NaCl transport capacity.  Under 
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normal circumstances, 25% of filtered sodium is reabsorbed in the loop and 5% to 10% is absorbed 
in the distal tubule. The added thiazide diuretic results in blockade of thiazide-sensitive electroneutral 
Na+Cl- receptors in the distal collecting duct, allowing more of the sodium presented to the distal tu-
bule to be excreted. In addition, the longer half-life of thiazides, as compared with loop diuretics, may 
also help prevent diuretic rebound[128]. 
    A significant increase in diuresis with the addition of thiazides is well documented in many studies 
of subjects with normal and significantly impaired renal function[129]. When thiazides and loop diuret-
ics are combined, there is an increased risk of hypokalemia and hyponatremia[125]. Given the litera-
ture suggesting increased mortality with higher doses of loop diuretics[110], the addition of a thiazide 
to a low or medium dose of a loop diuretic may be preferable to maintenance of high doses of a loop 
diuretic alone.
Fig. 10 – DOSE study: no differences between bolus vs. continuous infusion or between low and high doses of furosemide. (Source: Felker 
GM, et al. N Engl J Med, 2011. 364: p. 797-805.[123]).
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3.7.2 Precipitating factors for heart failure decompensation related with pharmacologic 
treatment
  Relapse of CHF in patients with previously stable compensated HF may be caused by deteriorating 
ventricular function, but several precipitating factors have been suggested[132]. The common factors 
that precipitate acute decompensated HF are[7]: 
1. Non-adherence with medication regimen, sodium and/or fluid restriction;
2. Acute myocardial ischemia;
3. Uncorrected high blood pressure;
4. AF and other arrhythmias;
5. Recent addition of negative inotropic drugs (e.g., verapamil, nifedipine, diltiazem, BB);
6. Pulmonary embolus;
7. Initiation of drugs that increase salt retention (e.g., steroids, thiazolidinediones, NSAIDs);
8. Excessive alcohol or illicit drug use;
9. Endocrine abnormalities (e.g., diabetes mellitus, hyperthyroidism, hypothyroidism);
10. Concurrent infections (e.g., pneumonia, viral illnesses);
11. Additional acute cardiovascular disorders (e.g., valve disease endocarditis, myopericarditis, aor-
tic dissection).
a.1) Low adherence
  Adherence describes a health related behavior of a person that adheres to the recommendations of 
a doctor, other health care provider, or investigator in a research project. The word “adherence” aims 
to avoid the authoritarian associations of “compliance”, formerly used to describe this behavior[130-
133], because “compliance” suggests that the patient is passively following the doctor’s orders and 
that the treatment plan is not based on a therapeutic alliance or contract established between the pa-
tient and the physician[134]. Both terms are imperfect and uninformative descriptions of medication-
taking behavior. Unfortunately, applying these terms to patients who do not consume every medica-
tion at the desired time can stigmatize these patients in their future relationships with health care 
providers[133-135]. It is clear that the full benefit of the many effective medications that are available 
will be achieved only if patients follow prescribed treatment regimens reasonably closely.
  Poor adherence limits  the effectiveness of proven therapies, resulting in lost opportunities to reduce 
mortality and readmission rates (Fig. 11). Indeed, poor adherence accounts for up to two thirds of 
preventable admissions in HF and coronary artery disease[136], and is  associated with mortality in pa-
tients with other chronic illnesses, including breast cancer, asthma and rheumatoid arthritis [130, 
136-139]. 
  Rates of adherence for individual patients are usually reported as the percentage of the prescribed 
doses of the medication actually taken by the patient over a specified period. Some investigators 
have further refined the definition of adherence to include data on dose taking (taking the prescribed 
number of pills each day) and the timing of doses (taking pills within a prescribed period)[134]. Adher-
ence rates are typically higher among patients with acute conditions, as compared with those with 
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chronic conditions; persistence among patients with chronic conditions is disappointingly low, drop-
ping most dramatically after the first six months of therapy[137-139].
  The average rates of adherence in clinical trials can be remarkably high, owing to the attention 
study patients receive and to selection of the patients, yet even clinical trials report average adherence 
rates of only 43  to 78  percent among patients receiving treatment for chronic conditions[134, 139, 
140].
Fig. 11 – Factors that determine adherence. (Source: Osterberg L, Blaschke T. N Engl J Med, 2005. 353: p. 487-97.[130]).
  There is  no consensual standard for what constitutes adequate adherence. Some trials consider 
rates of greater than 80 percent to be acceptable, whereas others consider rates of greater than 95 
percent to be mandatory for adequate adherence, particularly among patients with serious conditions. 
Although data on adherence are often reported as dichotomous variables (adherence vs. nonadher-
ence), adherence can vary along a continuum from 0 to more than 100 percent, since patients some-
times take more than the prescribed amount of medication[134].
  The ability of physicians to recognize nonadherence is poor, and interventions to improve adher-
ence have had mixed results. Furthermore, successful interventions generally are substantially com-
plex and costly[134, 141, 142]. Poor adherence to medication regimens accounts for substantial 
worsening of disease, death, and increased health care costs in the US[134, 143].
  Of all medication-related hospital admissions in the United States, 33  to 69 percent are due to poor 
medication adherence, with a resultant cost of approximately $100 billion a year[134]. Participants in 
clinical trials who do not follow medication regimens or placebo regimens have a poorer prognosis 
than subjects in the respective groups who do[134, 144]. Adherence to medication and placebo 
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
regimens, therefore, both predict better outcomes, and collecting adherence data from subjects is 
now considered an essential part of clinical trials[134].
  Research on adherence has typically focused on the barriers patients face in taking their medica-
tions. Common barriers  to adherence are under the patient’s control, so that attention to them is a 
necessary and important step in improving adherence. In responses to a questionnaire, typical rea-
sons cited by patients for not taking their medications included forgetfulness (30%), other priorities 
(16%), decision to omit doses (11%), lack of information (9%), and emotional factors (7%); 27% of the 
respondents did not provide a reason for poor adherence to a regimen[134].
  Physicians can contribute to patients’ poor adherence by prescribing complex regimens, failing to 
explain the benefits and side effects  of a medication adequately, not giving consideration to the pa-
tient’s lifestyle or the cost of the medications, and having poor therapeutic relationships with their pa-
tients[134, 145-147].
  More broadly, health care systems create barriers to adherence by limiting access to health care, 
using a restricted formulary, switching to a different formulary, and having prohibitively high costs for 
drugs, co-payments, or both[134, 148, 149]. An expanded view that takes into account factors under 
the patient’s  control as well as interactions between the patient and the health care provider and be-
tween the patient and the health care system are expected to have the greatest effect on improving 
medication adherence[134].
  Important self-care behaviors capable of underlying an acute HF episode are non-adherence to salt 
and caloric restriction and alcohol abstinence, but also non-adherence with medications and expo-
sure to drugs that are (relatively) contraindicated.
  Non-adherence to medication and diet has repeatedly been identified as a frequent precipitating fac-
tor for admission to hospital for decompensated HF [132, 150]. This  may represent an important bar-
rier to effective treatment of CHF [132]. In fact, non-adherence to diuretic therapy may result more 
rapidly in increasing symptoms than that to other drug classes, whose effect is more long-term.
  Moreover, when therapies are initiated in the hospital, outpatient adherence is improved as well as 
long-term outcomes[151-153]. Predischarge identification of patients with risk factors for nonadher-
ence may provide opportunities to target preventable admissions through disease management 
plans[151].
a.2) Measurement of low adherence in HF
  Assessing the degree of adherence is necessary in order to evaluate the effectiveness of prescribed 
treatments and to determine if the treatment is responsible for the changes in health outcomes. Varia-
tions in non-adherence prevalence rates must be cautiously interpreted as the measurement method 
and operational definitions vary. Adherence rates have been reported as the percentage of patients 
who are adherent or non-adherent, the number of patients achieving 70 –90% adherence, the per-
centage of full compliant days, or a particular score on a compliance/adherence scale. Regardless of 
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the definition used, in HF, many investigators have shown that selective adherence is common and 
non-adherence with some aspect of the medical regimen ranges from 5.52-64%[150, 151, 153-157].
  In the GWTG-HF[151], rates of adherence with the each of the Joint Commission core meas-
ures[151] for patients with non-adherence ranged from 83% to 94%. This is higher than what was 
reported in the OPTIMIZE-HF registry[136, 154] from 2003  to 2004 where the adherence rates for 
each of the core measures ranged from 54% to 87% and the ADHERE registry[153] from 2002 to 
2003  where the adherence rates ranged from 24% to 86%. Improved adherence in the GWTG-HF 
database may reflect more contemporary trends as well as an emerging emphasis on documentation 
of these measures. It is also possible that a quality improvement program like GWTG-HF may en-
hance evidence-based care by providing clinicians with real-time guideline reminders[151]. 
  The best method of measuring medication adherence is by the direct method of observation. How-
ever, because this approach is rarely feasible, indirect methods such as pill count, self-report, collat-
eral reports, clinical outcomes, prescription refills  or electronic event monitoring (EEM) are usually 
used. Although an indirect method, EEM has high sensitivity and allows the visualization of medication 
taking dynamics[157]. In the study of Wu et al., receiver operating characteristic curves showed that 
adherence rates above 88% produced the optimal combination of sensitivity and specificity with re-
spect to predicting better event-free survival [2.2 by dose count (p= 0.021) and 3.2 by dose day 
(p=0.002)][158].
  In HF, studies of patient adherence have focused on medication use and behavioral issues such as 
dietary practices, exercise, daily weight measurements and smoking cessation. Adherence to the 
medication and dietary regimen are essential if persons with HF are to remain stable and avoid re-
hospitalization. Most studies of adherence have used self-report measures, a method known to un-
derestimate non-adherence[157] and have retrospectively assessed adherence using indirect meth-
ods, typically self-report estimates, in patients readmitted to the hospital. Very few investigators have 
described adherence in the general HF population, but those that have differ widely. For example, re-
sults of a general HF population study found only 10% were fully adherent while 71–74% of patients in 
a specialized HF clinic were found to totally comply by taking all prescribed medications. In ambula-
tory HF patients, indirect measurements of medication adherence also varied widely, as described 
below[157].
  Although it is  challenging to compare findings from studies using different methods to evaluate 
medication compliance, the summary message is that adherence is an issue, and that patients find it 
easier to comply when medications are administered less frequently[157].
a.3) Characteristics of low adherent HF patients
  In some studies the characteristics of the non-adherent HF patients were studied. In the study of 
Michalsen et al.[155] there were no significant sex or subgroup differences relating to adherence to 
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medical and dietary treatment. In two patients heavy alcohol intake was noted; these were both non-
compliant with respect to drug treatment. The non-compliant patient group tended to be younger 
than the compliant group (72.2 (10.5%) vs  77.4 (9.7%) years) and to have a greater number of pre-
scribed drugs (4.0 (1.5%) vs  3.7 (1.4%)). In the Amberdaker et al. study patients with non-adherence 
were more likely to be young, male, minority, and uninsured. In addition, non-adherent patients were 
more likely to have non-ischemic cardiomyopathy, lower EF, and more frequent prior HF admissions 
(Table 3). 
Table 3 – Patient characteristics associated with low adherence. (Source: Ambardekar AV, et al. Am Heart J, 2009. 158: p. 644-52.[147]).
    Physical examination and laboratory findings at admission among non-adherent patients were no-
table for greater volume overload as evidenced by higher body weight, increased presence of jugular 
venous distention, rales, and edema on examination as well as higher BNP levels. Some HF prognos-
tic variables such as blood pressure, BUN, and troponin, appeared to reflect lower disease severity in 
non-adherent patients, whereas other prognostic measurements such as BNP level, EF, and number 
of prior HF admissions were less favorable in non-adherent patients. In multivariate analysis, younger 
age, male gender, minority race, and lack of insurance were independently associated with non-
adherence[151].
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  Within the population of patients with non-adherence, differences between dietary only, medication 
only, and both dietary and medication non-adherence were examined. Patients with medication non-
adherence as a component of their non-adherence versus dietary non-adherence alone were more 
likely to be young, male, minority, and uninsured. This subpopulation also tended to have increased 
rates of non-ischemic cardiomyopathy, alcohol abuse, tobacco dependence, as well as lower EF. By 
contrast, diabetes and higher body mass index were more prevalent among those with dietary non-
adherence. Patients with combined medication and dietary non-adherence were almost twice as likely 
to have had ≥2 HF admissions in the previous 6 months as well as considerably higher BNP lev-
els[151]. 
a.4) Consequences of the low adherence to medications in HF patients
  In the OPTIMIZE-HF[154] study non-adherence to medications, non-adherence to diet, and uncon-
trolled hypertension each were associated with shorter stay and lower in-hospital mortality. Patients 
with non-adherence to medications or diet are likely to be admitted with excessive sodium retention. 
These patients may more readily achieve compensation in response to salt restriction, adjustment of 
diuretics, and provision of medications during the inpatient hospitalization. It should be noted that pa-
tients with non-adherence to medications or diet as an admission precipitant were at high-adjusted 
risk of 60- to 90-day post-discharge mortality and death/re-hospitalization similar to the overall HF 
population.
  In the GWTG-HF[151] study non-adherent patients were observed to have lower in-hospital mortality 
and shorter length of stay (Table 4). 
Table 4 – Hospital outcomes related with low adherence. (Source: Ambardekar AV, et al. Am Heart J, 2009. 158: p. 644-52.[147]).
  Even after adjusting for multiple variables of prognostic importance, non-adherence appeared to be 
independently associated with better in-hospital outcomes. Among the different subtypes of non-
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adherence, patients with dietary non-adherence alone tended to have the lowest unadjusted in-
hospital mortality. Non-adherent patients present with evidence of lower EF and greater volume over-
load, yet they have an in-hospital course characterized by a shorter length of stay and lower mortality. 
This suggests greater acuity of presentation but lower short-term disease severity, less difficulty in 
achieving stability with reinstitution of sodium restriction, fluid restriction, and/or medication, and po-
tentially preventable admission[151]. 
  In examining long-term outcomes, non-adherence has been associated with higher mortality and 
more frequent hospitalizations[136, 159]. Some poor prognostic markers among non-adherent pa-
tients including lower EF, more frequent prior admissions, and higher BNP levels. However, despite 
these markers, the non-adherent patients in our study had lower in-hospital mortality and shorter 
length of stay. The reasons why non-adherent patients had better in-hospital outcomes are unclear. 
Non-adherent patients were younger, had higher BP, and lower BUN levels—all markers of better 
prognosis in HF. It is plausible that it is easier to stabilize such patients by re-instituting sodium restric-
tion and resuming medical therapy. This suggests that if the cycle of low adherence is broken, clini-
cians may be able to improve long-term outcomes in this high-risk population.
  Low adherent patients were less often considered for ICD therapy, which may reflect a sense from 
clinicians that if patients were to become adherent with medications that improve cardiac remodeling, 
functional status and EF would improve obviating the need for ICD therapy[151].
  In addition, patients with medication non-adherence were less likely to receive several key evidence-
based medical therapies. The reasons for these differences are not clear. One possibility may be that 
medication non-adherence influences clinicians to be less likely to prescribe guideline-based thera-
pies, thus potentiating a cycle of non-adherence and hospital readmission. This represents another 
potential area for investigation[151].
b) How to study the impact of treatment related precipitating factors
    Pharmacoepidemiology explores drug efficacy or toxicity using large observational study designs. 
In the past few years, the number of pharmacoepidemiologic studies published in medical journals 
has increased, as these studies have explored drug-related questions that at times cannot be an-
swered by performing randomized trials[160]. There are four pharmacoepidemiologic study designs 
that may be used to explore the association between a specific pharmacologic agent and a disease 
of interest: cohort studies, case-control studies, case-crossover studies, and case-time-control studi-
es[160]. Self-matched case-only studies (such as the case-crossover or self-controlled case-series 
method) control by design for time-invariant confounders (measured or unmeasured), but they do not 
control for confounders that vary with time. A bidirectional case-crossover design can be used to ad-
just for exposure-time trends[161].
b.1) Case-time-control study
    It has become clear by now that a major concern in studying adverse drug reactions is how to deal 
with transient exposures followed by a short steep increase in risk and the dependency of therapy 
with the severity of a disease or comorbidities, called confounding by indication.
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    To overcome these causes of bias a study design using only exposure histories of cases was intro-
duced in 1991[160, 162]. Briefly, the case-crossover design is  like a retrospective crossover experi-
ment except the subjects not the investigator decide when to crossover between exposed and unex-
posed periods, and the exposure history is obtained only for subjects who had outcomes[162].
    One version of the case-crossover design can be imagined as a matched case-control design 
where the controls  are the same persons as the cases before the event under study occurred[162] 
(Fig. 12). 
Fig. 12 – Case-crossover design. (Source: Schneeweiss S, et al. Pharmacoepidemiol Drug Saf, 1997. 6 Suppl. 3: p. S51-S59.[158]).
  In crossover studies only persons with ‘discordant' exposure in the time windows contribute infor-
mation: cases that are exposed at the time of event but unexposed in the control period or vice versa. 
Therefore, an efficient application of crossover designs would be an exposure that is varying over time 
as drug usage often is[162].
 Case-crossover designs are appropriate but raise important methodological challenges, namely 
those related with the definition of the proper windows of exposure or the recall of past exposures – 
more evident when evaluating poorly educated elderly patients, or when long-term recall is intended. 
By using each subject experiencing the outcome (case) as his own control (the exposure observed in 
each case close to the occurrence of the outcome is compared with his own exposure in a previous 
period) in case-crossover designs, the “cases” and the “controls” are comparable in most of their 
known and unknown confounders overcoming most of the between-person confounding by constant 
characteristics. Within-person confounding by transient factors (e.g. fluctuations in disease severity, 
co-morbidities), however, is still possible. Temporal trends in the exposures, especially if the defined 
windows of exposure or the period between the windows are too long, may warrant further correction 
of the risk estimates. These designs allow a finer control of confounding, including confounding by 
chronic indication, than most other observational studies, and may be seen as an efficient variant of 
the matched case-control design, each case being matched with himself. The period of observation 
closest to the occurrence of the event corresponds to the exposure experience of the cases and pre-
vious period(s) of observation correspond(s) to the exposure among matched controls[162].
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Three advantages are most noteworthy[160-162]: 
1. When a researcher is dealing with a time-varying or intermittent exposure a case-crossover study is 
especially valuable since the time window of interest can be varied easily;
2. In crossover studies the same person is both case and control. This  means that cases and con-
trols are comparable in most of their known and unknown confounders except for intermittent ex-
posures. This overcomes the problem of between-person confounding  by constant characteris-
tics. This includes confounding by chronic indication as a common cause of bias in pharmacoepi-
demiology;
3. In contrast to case-control studies the sometimes difficult and time consuming control sampling 
process is unnecessary;
There are five potential disadvantages[160-162]: 
1. Within-person confounding by transient factors, including fluctuations in disease severity or co-
morbidities i.e. confounding by acute indication, is still possible;
2. Although bias in the selection of a control person is  impossible because each case serves as his or 
her own control, it is still possible for bias in selection of the control time window(s). 
3. Time trend bias may occur if the case and control time windows are very long because there may 
have been changes in the usual prescribing pattern or dose of the drug of interest;
4. When the exposure is retrospectively assessed, the chance of differential misclassification and 
measurement error of exposure still exists;
5. Is often impossible to study death as an outcome since a detailed retrospective drug exposure 
assessment obtained by proxy interview is likely to be prone to substantial errors.
  The case-time-control design is a variant of the case-crossover. It comprises, in addition to a regular 
case-crossover, the selection of an independent control group, as in a case-control study. The case-
crossover analysis of the exposure history from controls (controls compared with themselves, just as 
cases in the case-crossover analysis) (Fig. 13) may be used to estimate the background trend in use 
of the drugs under study (or seasonal exposure to other precipitating factors) which is not expected to 
be a major concern in our study, given the relatively short period to which the evaluation of exposures 
refer. It may also be used to control other kinds of control-time selection bias and recall bias, and both 
justify the option for this design in the present investigation. The ratio of the OR from the case-
crossover study by the OR obtained in this  “control-crossover” analysis  will provide a less biased OR 
estimate for the precipitating effect of the exposures under study[160-162]. 
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Fig. 13 – Selection of the control group and exposure time in case-crossover studies. (Source: Rothman KJ, Greenland S. Modern 
Epidemiology.Philadelphia, Pa: Lippincott; 1998.[160]).
  In the case-time-control design control are recruited at the same time as the cases. Both, cases and 
controls are asked for their present exposure at the time of event and at their past exposure in the 
control period. The rough synchronization of cases allows for an estimation of a common time trend 
e.g. increasing exposure over time through changes in prescribing patterns in comparison to the more 
general case-control-crossover design that control for individual and short-term time trends. By ob-
serving two time periods in the group of control persons, a time trend of exposure in the source popu-
lation can be estimated through a trend odds ratio or control-crossover exposure odds ratio[162].  
  Suissa[161] showed that dividing the case-crossover exposure OR by the trend OR would produce 
an OR adjusted for time trend and controlled for between-person confounding[162].
  Greenland[162] has shown that this  adjustment cannot be universally valid: the time trend among 
cases could be very different from the time trend among controls and may itself be confounded by 
indication, introducing a new bias, larger than the original time trend bias it is aiming to adjust for. This 
leads to the recommendation to use case-crossover designs when there is hard to control confound-
ing and at the same time no or a small amount of within-person confounding via a time trend (more 
likely, the closer the event and control periods are) and case-time-control designs are preferable if a 
strong time trend in cases and controls is likely[162]. 
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4. OBJECTIVES
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Low adherence to medication regimen, sodium and/or fluid reduction has been identified as a trigger-
ing factor for acute heart failure (HF) decompensation[7]. Diuretics, though not established as specific 
long-term prognostic modifiers, are cornerstone in HF symptomatic management. However, the im-
pact of low adherence to therapy and its prognostic implications is undetermined yet. The impact of 
the triggering effect of low adherence is hard to measure since the consequences may be acute but 
the determinants and exposure may be variable along the time.
With our study, we aimed to quantify the effect of low adherence to loop diuretic therapy as a trigger 
for acute decompensation in chronic HF patients, using a case-time-control design.
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
5. MANUSCRIPT
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Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart 
failure
Abstract 
Introduction: Heart failure (HF) is associated with substantial morbidity, impaired quality of life and hu-
ge costs, in large part related with hospitalizations. Diuretics are required for the symptomatic mana-
gement of HF but the role of therapy adherence in preventing hospital admissions is incompletely un-
derstood. 
Objectives: To quantify the effect of low adherence to loop diuretic therapy as triggering factor for 
chronic HF decompensation. 
Methods: Case-time-control design using a conditional logistic regression analysis of a case-crosso-
ver of cases – patients with acute decompensation of chronic HF and controls - patients with stable 
chronic HF. Adherence was assessed by a semi-quantitative questionnaire and classified as low if less 
than 88% of prescribed doses of furosemide were taken in the preceding week.
Results: Case patients were older, most were women and with severe left ventricular systolic dysfunc-
tion (LVSD) from ischemic etiology. Risk factors and comorbidities prevalence was higher in cases, 
including arterial hypertension, diabetes mellitus, atrial fibrillation, chronic obstrutive pulmonary disea-
se and anemia, with the exception of chronic kidney disease. Cases were less frequently under angio-
tensin converting enzyme inhibitors (ACEI) or beta-blockers. The prevalence of low adherence was 
17% (108  patients) in the case arm and 15% (86 patients) in the control arm. Among cases, low ad-
herence to diuretic therapy was 3-fold and significantly more likely in the week preceding hospitaliza-
tion than 4 weeks earlier (OR=3.00, 95% CI 1.09–8.25, p=0-033). Among controls, the difference in 
reported adherence was smaller and marginally significant (OR=1.50, 95% CI 0.72–3.11, 0.277). The 
case-time-control OR for low adherence was 2.00. This triggering effect was stronger among older 
patients, in women, with severe LVSD, without risk factors and comorbidities, and under treatment 
with ACEI. 
Conclusions: An adherence rate below 88% dose-counts of loop diuretic in chronic HF patients dou-
bles the risk of decompensation in the following week. The identification of patient groups in which 
low adherence effect is stronger may enable timely application of adherence improvement measures.
Keywords
Heart failure; hospitalizations; heart decompensation; diuretics; furosemide; medication adherence; 
case-time-control study.
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Introduction
    Heart failure (HF) is the primary diagnosis in >1 million hospitalizations annually and the leading 
cause of hospitalization among patients > 65 years of age. The number of hospitalizations has 
increased, but little is known about its etiology and re-hospitalization imposes a high burden on the 
health care system with adverse impact in long-term outcomes[1]. Patients hospitalized for HF are at 
high risk of re-hospitalization[2].
    The acute HF syndromes have a heterogeneous presentation[2, 3]. Worsening chronic HF (CHF) 
occurs in patients who have a history of CHF (HF stage C according to the ACC/AHA guidelines) and 
present with acute or increased symptoms and signs typical of HF. This group accounts for the 
majority (80%) of patients hospitalized with acute HF syndromes[2, 3].
    Considering the causes of decompensation, the burden attributed to effects of pharmacological 
exposures is unknown. Low adherence to medication and diet has repeatedly been identified as a 
precipitating for hospital admission due to acute decompensated HF[4, 5] in 5.5-64%[1, 5-11] of 
hospitalized patients mainly in observational studies which measure global adherence to treatment or 
registries. The effects of diuretics on mortality and morbidity have not been studied in patients with 
HF: a formal evaluation in randomized trials in HF hard outcomes became impossible as they are 
necessary for symptomatic management[2, 12-16] and recommended for this reason in patients with 
signs and symptoms of congestion, irrespective of ejection fraction (EF)[2, 12]. The adherence to loop 
diuretic therapy is particularly hard to quantify since guidelines on diuretic treatment adjustments do 
not exist and exposure to diuretic and the determinants  of prescription are variable along time[2, 12, 
17]. Low adherence to diuretic therapy may result more rapidly in increasing symptoms than to other 
drugs suggesting a powerful triggering effect with acute and long-term implications. 
    We aimed to quantify the effect of low adherence to loop diuretic therapy as triggering factor for 
chronic HF decompensation.
Methods
a. Study design
    For the assessment of the effect of low adherence to loop diuretic therapy as a triggering factor for 
acute decompensation of chronic heart failure we implemented a case-time-control study [18-20]. It 
comprises a case-crossover of the population with acute decompensation of chronic heart failure (ca-
se arm) and a selection of an independent control group (control arm) in which the unfavourable clini-
cal outcome is not present. The case-crossover analysis of the exposure history from controls (con-
trols compared with themselves, just as cases in the case-crossover analysis) is used in this study 
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mainly to control the effect of self-report and recall bias, justifying the option for this design in our 
study. Also, it helps to estimate the background trend in use of the drugs under study (or seasonal 
exposure to other precipitating factors) which is  not expected to be a major concern in our study, gi-
ven the relatively short period to which the evaluation of exposures refer. 
    Cases for case-crossover analysis were subjects hospitalized at a teaching tertiary care hospital, 
between May 2009 and January 2011 due to decompensated chronic HF, defined by an increase of 
at least one New York Heart Association (NYHA) class in patients with chronic HF, diagnosis based on 
the European Society of Cardiology criteria (from EDIFICA[21, 22] cohort).  
    Controls for case-time-control study were stable chronic HF patients (no hospitalization due to de-
compensated HF in the previous 3  months) followed at the HF outpatient clinic of the same hospital 
between January 2011 and July 2012. 
    Case-time exposure was the week preceding the outcome - hospitalization, for cases, or the time 
of enrollment in the study, for controls. The control-time exposure was the fourth week before the in-
dex time (Fig 1) in both groups. Exposure was assessed retrospectively by self-report or for surroga-
tes respondents whenever the patient was unable to fill the questionnaire by clinical reasons (the pa-
tient forgot, was uncooperative or presented with neurologic impairment like cognition and memory 
disturbances or aphasia) 
    Our questionnaire included semi-quantitative evaluation of adherence to furosemide in both case 
and control-time exposure and in the three possible periods of prescription - morning, afternoon and 
night (Appendix). This evaluation ranged between 9 possible classifications, in case-time in both 
groups and in the control-time in the cases: furosemide not prescribed in that period, all the prescrip-
tions were taken and number of missed prescriptions - 1, 2, 3, 4, 5, 6 to 7 missings in a week. In the 
control-time of the control arm the classification ranged between 5 classifications: furosemide not 
prescribed at that period, all the prescriptions were taken and missing prescriptions - 1 to 3  missings, 
4 to 6 missings and 7 missings in a week. In the cases, the self reported questionnaire was applied 
within the first 48  hours after hospitalization due to decompensated chronic HF. In the control arm the 
questionnaire was applied to patients with stable therapeutic regimen.
b. Sample
    From the initial 662 eligible patients from the EDIFICA cohort, 185 were considered non-eligible 
because 1 had right HF, 84 were admitted with de novo acute HF, 77 did not have loop diuretic 
prescribed, 6 died before questionnaire filling and 17 were unable to fill the questionnaire by clinical 
reasons. Then, from 477 eligible patients, 152 were excluded because the questionnaire was not 
applied to 149 patients and in 3  patients there were missing data about the exposure to furosemide 
(Fig. 2). Thus, 325 patients were included in the case-arm. They presented a median age of 78  years, 
with similar gender distribution (49% were male) (Table 1). Ischemic etiology was present in 43%, 35% 
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had severe LVSD with a mean EF of 40%. Arterial hypertension (was the most prevalent risk factor 
(71%). Atrial fibrillation (AF) was the most prevalent comorbidity (50%). Only 19% had chronic 
obstructive pulmonary disease (COPD) documented. Renin-angiotensin-aldosterone blockade was 
present in 67% (53% were under angiotensin conversion enzyme inhibitors – ACEI - and 14% under 
angiotensin receptor blockers – ARB) and 56% were under beta-blockers (BB). The median dose of 
furosemide prescribed was 80 mg, 118  patients had furosemide prescribed once daily, 187 had two 
times daily and 20 had three times daily. The main cause to acute HF decompensation attributed by 
the physician was infection (37%) followed by subjective appreciation of poor adherence to treatment 
(27%).
    The included and excluded patients from the case-arm presented similar baseline characteristics, 
namely age distribution, HF etiology and severity, risk factors and comorbidity prevalence and 
prognosis modifiers treatments. There were more man in the included (49% vs. 28%, p <0.001). 
Arterial hypertension was more prevalent in the excluded patients (82% vs. 71%, p=0.014). Although 
the median daily dose of furosemide was the same, more of the included patients were under high 
doses of furosemide (p=0.027). Considering the decompensation causes, assessed by the physician, 
infection was attributed more frequently as a decompensation cause in the excluded patients (49% 
vs. 37%, p=0.023). The proportion attributed to poor adherence as cause of decompensation was 
similar between groups (Table 1). 
    From the initial 343  stable outpatients during the study period, 47 patients were non-eligible 
because they did not have loop diuretic prescribed. From the 296 eligible patients, 4 patients were 
excluded, because in 2 patients the questionnaire was not applied and in 2 patients there were 
missing data about the exposure to furosemide. Thus, 292 patients were included in the control arm 
(Fig. 2). 
c. Statistical analysis
    Numerical variables are presented as mean (standard deviation) if normally distributed or median 
(interquartile range) if non-normally distributed. Categorical variables are presented as count (percent). 
For comparisons between groups, the chi-square test was used to compare categorical variables, a 
two independent-sample t test was used to compare normally distributed continuous variables, and 
the Mann–Whitney U test was used for continuous skewed variables. 
    Adherence was classified as low if less than 88% of prescribed doses were taken in the preceding 
week, a cut-off previously used in other studies since receiver operating characteristic curves showed 
that adherence rates above 88% produced the optimal combination of sensitivity and specificity with 
respect to predicting better event-free survival [2.2 by dose count (p=0.021) and 3.2 by dose day 
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(p=0.002)][23]. 
    A conditional logistic regression[24-26] was used to quantify the risk of low adherence to loop diu-
retics as a trigger of acute decompensated HF. A case-time-control OR was estimated by correcting 
the OR from the case-arm with the OR from the control-arm. 
    All of the analyses were conducted using Stata 11 (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP) and a p<0.05 was considered to be statistically signi-
ficant.
d. Ethics
    The study protocol was according with the Declaration of Helsinki, the local ethics committee of 
Centro Hospitalar São João approved the study and patients gave informed consent.
Results
a. Baseline characteristics 
    The baseline characteristics of the study sample in each arm are shown in table 2. When 
comparing the patients between the two arms we found that the cases were older (78  vs. 73  years, p 
<0.001), with a lower proportion of male patients (49% vs. 65%, p<0.001). Patients from control arm 
presented more frequently with severe LVSD (35% vs. 59%, p<0.001) mainly with ischemic etiology. 
The prevalence of risk factors – arterial hypertension and diabetes mellitus – and comorbidities - AF, 
COPD and anemia - was higher in cases with the exception of the presence of chronic kidney disease 
(CKD), more prevalent in controls (28% vs. 35%, p <0.001). Cases were less frequently under 
treatment with ACEIs (53% vs. 76%, p <0.001) and BB (56% vs. 89%, p<0.001). 
b. Prevalence of low adherence to loop diuretic therapy
    The prevalence of low adherence to loop diuretic therapy in each exposure period, overall and 
stratifying by patient characteristics is shown in table 3. In the case arm, low adherence was 
documented in 108  patients (17%), 59 (18%) in the case-week and 49 (15%) in the control-week. In 
the control arm, low adherence was documented in 86 patients (15%), 46 (16%) in the case-week 
and 40 (14%) in the control-week. Stratifying by patient characteristics, in the case arm, the 
prevalence of low adherence was higher in younger patients (age < 70 years), males, with ischemic 
etiology and severe LVSD, without arterial hypertension, CKD, AF or anemia, without treatment with 
ACEI and under treatment with ARB  and BB. The prevalence was similar in diabetes mellitus and 
COPD. In the control arm, there were some differences, since low adherence was more prevalent in 
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older patients, female, with non-ischemic etiology and non-severe LVSD, without diabetes mellitus 
and with AF. Those patterns were similar in case and control week in both arms.
c. Effect of low adherence to loop diuretic therapy
    Among cases, low adherence to diuretic therapy was 3-fold and significantly more likely in the week 
preceding hospitalization than 4 weeks earlier (OR=3.00, 95% CI 1.09–8.25, discordant pair ratio 
15/5). Among controls, the difference in reported adherence was smaller and marginally significant 
(OR=1.50, 95% CI 0.72–3.11, discordant pair ratio 18/12) (Table 4). 
    After stratifying by patient characteristics, we found that low adherence to loop diuretic therapy had 
a stronger effect as trigger for decompensation in older patients (3-fold) with no effect in younger 
patients, in females (over 4-fold) with a smaller effect in males (40%), in patients with severe LVSD 
(over 3-fold) and marginally in patients with non-severe LVSD (25%). The effect was higher in patients 
without risk factors or comorbidities: over 3-fold higher in non-diabetic patients, in patients without 
arterial hypertension or CKD and over 2-fold higher in patients without AF or anemia. When stratifying 
to prognosis modifying therapies, the effect of low adherence to loop diuretic therapy was over 3-fold 
higher in patients  under ACEI and BB, with no effect in those not treated with ACEI but over 2-fold 
higher in patients not treated with BB and not treated with ARB (Table 4).
Discussion
    In our case-time-control study we showed that an adherence rate below 88% dose-counts of loop 
diuretic in chronic HF patients doubles the risk of decompensation in the following week. ‘Adherence 
to’ describes a health related behavior of a person that adheres to the recommendations of a doctor, 
other health care provider, or investigator in a research project[27]. Low adherence to medication and 
diet has repeatedly been identified as a frequent precipitating factor for admission to hospital for acute 
HF decompensation [1, 2, 6, 28]. This may represent an important barrier to effective treatment of 
chronic HF[28]. Adherence rates have been reported as the percentage of patients who are adherent 
or non-adherent, the number of patients achieving 70 –90% adherence, the percentage of full 
compliant days, or a particular score on a compliance/adherence scale[1, 5-11]. Regardless of the 
definition used, in HF, many investigators have shown that selective adherence is common and 
globally low adherence with some aspect of the medical regimen ranges from 5.5-64%[1, 5-11]. In 
our study, we observed lower rates of low adherence to diuretic therapy, documenting higher values 
of mean adherence than previously reported – 92% in cases and 95% in controls. This may be due to 
the fact that he rates previously available are mainly from registries, in which was not determined 
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adherence exclusively to diuretic therapy, and to the fact that most of the patients included in our 
study were previously followed in our HF clinic, expected contribution to higher rates of adherence. 
Even though, these rates are higher than previously shown in studies on HF clinics[10].
    Low adherence to therapy has been associated with higher mortality and more frequent 
hospitalizations [1, 5-11, 29] with high-adjusted risk of 60- to 90-day post-discharge mortality and 
death/re-hospitalization similar to the overall HF population[7, 23]. However, the triggering effect of 
low adherence to loop diuretic therapy and its  contribution for acute HF decompensation is  harder to 
define. Also, studies on its impact are lacking. The low frequency to the exposure enables the 
interpretation of a risk to decompensation in the presence of low adherence: the trigger effect. After 
estimating the OR for low adherence in cases and controls, the result of the case-time-control design 
may be assumed as the risk of decompensation in the following week if exposed to the trigger – low 
adherence to diuretic therapy. 
The triggering effect was stronger among older patients, in women, with severe LVSD, without risk 
factors and comorbidities and under treatment with ACEI suggesting that adherence to loop diuretic 
therapy is very important in the more severe patients, the low adherence is documented as an exclu-
sion cause in patients  without other known important triggers and also polymedication and its ad-
verse effects may be important for the exposure and the impact of low adherence to loop diuretic 
therapy. Also the effect was high in both groups of patients treated or not with BB suggesting also 
different patterns of adherence to other therapies for when compared with ACEI. According to previ-
ous studies[7, 23], patients with documented low adherence to therapy were associated with shorter 
stay, lower in-hospital mortality, more readily achieve compensation in response to salt restriction, ad-
justment of diuretics, and provision of medications during the inpatient hospitalization. This suggests 
that patients have a hypervolemic status in which institution of appropriate treatment results in fast 
clinical improvement implying reduced contribution to decompensation of severity of disease and 
presence of risk factors or comorbidities. The ability of physicians to recognize interventions to im-
prove adherence had mixed results[30-32]. Observational studies may help to identify clinical profiles 
more probably related with low adherence to diuretic therapy and establish timely measures in order 
to improve it since.
   A major concern in studying adherence to therapy is  how to deal with transient exposures fol-
lowed by a short steep increase in risk and the dependency of therapy with the severity of a disease 
or comorbidities, called confounding by indication. In order to overcome those problems, we per-
formed a case-time-control study. The case-time-control design is a variant from a case-crossover 
design that is able to distinguish between continued and transient exposures as drug use often vari-
able in time, especially if we consider patterns of adherence or exposure to drugs. Dividing the resul-
tants OR from a case and control arm, the case-time-control will give us a less biased OR estimate for 
the precipitating effect of the exposures under study. In crossover studies only persons with ‘discor-
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dant' exposure in the time windows contribute with information: cases that are exposed at the time of 
event but unexposed in the control period or vice versa. Therefore, an efficient application of cross-
over designs would be an exposure that is varying over time as diuretic therapy often is[29, 30]. In our 
study, the main objective in using this  design was to control the impact of self-reported and recall 
bias.
    There was a differential classification of exposure in the control arm, as in the control time there 
were only 5 options of missing doses, leading to less precise answers. To the analysis, we choose to 
correct those options turning them as mean missing doses, that means that every patients that an-
swered as having missed between 1 to 3  doses in the control time week were considered has having 
missed 2 and those who answered as having missed between 4 to 6  doses were considered has 
having missed 5. After comparing the answers between the case time and the control time of the 
control arm, we found that the OR in the control arm is, probably, overestimated because many of the 
observations in the case time were distributed by the lower extremes of both intervals (missed 1 dose 
and 4 doses a week), something that would probably happen on the controls if those options were 
available. This increased the number of discordant pairs in the control arm overestimating the OR for 
low adherence. That means that the real difference in the risk between cases and controls is probably 
higher.
    The main limitations of our study were the quality of self reported information and recall bias. Using 
the control group helped to decrease the possibility of information bias by attenuating the self-report 
effect. However, the recall bias remains, especially for cases, since the acute nature of the event may 
be a conditioning factor. Thus, differential misclassification may be present especially in the case arm. 
Those aspects also lead to the inclusion of a smaller number of patients since there was missing data 
about drug prescription. To overcome those problems, and since there is a variable exposure, pro-
spective evaluation may be helpful in order to quantify the effect of low adherence to diuretic therapy 
as a triggering factor for acute HF decompensation.
Conclusions
According to our study, an adherence rate below 88% dose-counts of loop diuretic in chronic HF 
patients doubles the risk of decompensation in the following week.
This triggering effect was stronger among older patients, in women, with severe LVSD, without risk 
factors and comorbidities and under treatment with ACEI. 
The identification of these profiles may enable the timely application of adherence improvement 
measures.
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Table 1 - Baseline characteristics of the case population and comparison between patients included 
and excluded in the case-crossover study.
Eligible
 n = 477
Included 
n = 325
Excluded 
n = 152 p-value
Age (years), median (IQR) 79 (13) 78 (12) 80 (12) 0.276
Male, n (%) 201 (42) 158 (49) 43 (28) <0.001
Ischemic etiology, n (%) 197 (41) 138 (43) 59 (39) 0.451
Severe LVSD, n (%) 160 (34) 113  (35) 47 (31) 0.532
Ejection fraction (%), mean (SD) 42 (18) 40 (17) 42 (18) 0.206
Diabetes mellitus, n (%) 203 (43) 135 (42) 68 (45) 0.528
Arterial hypertension, n (%) 355 (74) 231 (71) 124 (82) 0.014
CKD, n (%) 129 (27) 90 (28) 39 (26) 0.641
COPD, n (%) 87 (18) 60 (19) 27 (18) 0.854
AF, n (%) 233 (49) 161 (50) 72 (47) 0.659
Anemia, n (%) 224 (47) 155 (48) 69 (45) 0.639
ACEI, n (%) 243 (51) 172 (53) 71 (47) 0.206
ARB, n (%) 74 (16) 44 (14) 30 (20) 0.081
BB, n (%) 269 (56) 181 (56) 88 (58) 0.651
Furosemide dose (mg), median (IQR) 80 (40) 80 (80) 80 (40) 0.027
Decompensation cause, n (%)
     ACS 19 (4) 14 (4) 5 (3) 0.670
     Infection 196 (41) 121 (37) 75 (49) 0.023
     Elevated blood pressure 16 (3) 12 (4) 4 (3) 0.526
     AF 78 (16) 58 (18) 20 (13) 0.435
     Other rhythm disorders 10 (2) 7 (2) 3 (2) 0.834
     Anemia 62 (13) 39 (12) 23 (15) 0.274
     Poor adherence to treatment 126 (26) 88 (27) 38 (25) 0.889
ACEI - angiotensin conversion enzyme inhibitors; ACS - acute coronary syndrome; AF - atrial fibrillation; ARB - angiotensin receptor 
blockers; BB - beta-blockers; CKD - chronic kidney disease; COPD - chronic obstructive pulmonary disease; IQR - interquartile 
range; LVSD - left ventricular systolic dysfunction; SD - standard deviation.
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Table 2 - Comparison between the patients included in the case and control arms of the case-time-
control study.
Cases 
n = 325
Controls 
n = 292 p-value
Age (years), median (IQR) 78 (12) 73 (19) <0.001
Male, n (%) 158 (49) 189 (65) <0.001
Ischemic etiology, n (%) 138 (43) 108 (37) 0.035
Severe LVSD, n (%) 113 (35) 173 (60) <0.001
Diabetes mellitus, n (%) 135 (42) 103 (35) 0.104
Arterial hypertension, n (%) 231 (71) 187 (64) 0.062
CKD, n (%) 90 (28) 102 (35) <0.001
COPD, n (%) 60 (19) 65 (22) 0.241
AF, n (%) 161 (50) 126 (43) 0.112
Anemia, n (%) 155 (48) 100 (34) 0.001
ACEI, n (%) 172 (53) 222 (76) <0.001
ARB, n (%) 44 (14) 39 (13) 0.947
BB, n (%) 181 (56) 261 (89) <0.001
ACEI - angiotensin conversion enzyme inhibitors; ACS - acute coronary syndrome; AF - atrial fibrillation; ARB - angiotensin receptor 
blockers; BB - beta-blockers; CKD - chronic kidney disease; COPD - chronic obstructive pulmonary disease; IQR - interquartile range; 
LVSD - left ventricular systolic dysfunction.
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Table 3 - Prevalence of low adherence to loop diuretic therapy in each exposure period, among cases 
and controls, overall and stratifying by patient characteristics.
Cases with low adherence
n (%) = 108 (17)
Controls with low adherence
n (%) = 86 (15)
Case week
n (%)
.
Control week
n (%)
.
Case week
n (%)
.
Control week
n (%)
.
   Overall 59 (18) 49 (15) 46 (16) 40 (14)
   .
    Age (years)
        < 70       
        ≥ 70
.
15 (24)
44 (17)
13 (21)
36 (14)
22 (13)
24 (20)
18 (15)
22 (13)
.
    Gender
        Male
        Female
.
40 (25)
19 (11)
35 (22)
14 (8)
25 (13)
21 (20)
21 (11)
19 (18)
.
    Etiology
        Ischemic
        Non-ischemic
.
29 (21)
30 (16)
27 (20)
22 (12)
11 (10)
35 (19)
5 (5)
35 (19)
.
    LVSD
        Severe
        Non-severe
.
29 (26)
29 (14)
21 (18)
28 (14)
26 (15)
20 (17)
20 (12)
20 (17)
.
    Diabetes mellitus
        Yes 
        No
.
24 (18)
35 (19)
20 (15)
29 (15)
14 (14)
32 (17)
9 (9)
31 (16)
.
    Arterial hypertension
        Yes 
        No
.
40 (17)
19 (20)
35 (15)
14 (15)
26 (14)
20 (29)
23 (12)
17 (16)
.
    CKD
        Yes 
        No
.
10 (11)
49 (21)
8 (9)
41 (17)
12 (12)
24 (17)
8 (8)
24 (17)
.
    COPD
        Yes 
        No
.
11 (18)
48 (18)
12 (20)
37 (14)
7 (11)
39 (17)
4 (6)
36 (16)
.
    AF
        Yes 
        No
.
25 (16)
34 (21)
23 (14)
26 (16)
21 (17)
25 (15)
21 (17)
19 (11)
.
    Anemia
        Yes 
        No
.
18 (12)
41 (24)
15 (10)
34 (20)
16 (16)
30 (16)
12 (12)
28 (15)
.
    ACEI
        Yes 
        No
.
29 (17)
30 (20)
22 (13)
27 (18)
31 (14)
15 (21)
29 (13)
11 (16)
.
    ARB
        Yes 
        No
.
11 (25)
48 (17)
8 (18)
41 (15)
10 (26)
36 (14)
7 (18)
33 (13)
.
    BB
        Yes 
        No
.
38 (21)
21 (15)
29 (16)
20 (14)
41 (16)
5 (16)
34 (13)
6 (19)
ACEI - angiotensin conversion enzyme inhibitors; ACS - acute coronary syndrome; AF - atrial fibril-
lation; ARB - angiotensin receptor blockers; BB - beta-blockers; CKD - chronic kidney disease; CI 
- confidence interval; COPD - chronic obstructive pulmonary disease; LVSD - left ventricular sys-
tolic dysfunction.
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Table 4 - Effect of low adherence to loop diuretic therapy as a trigger for heart failure decompensation 
estimated by conditional logistic regression, overall and stratifying by patient characteristics.
Case arm Control arm Case-time-control
OR 95% CI p OR 95% CI p OR
   Overall 3.00 1.09-8.25 0.033 1.50 0.72-3.11 0.277 3.00 / 1.50 = 2.00
   .
    Age (years)
        < 70       
        ≥ 70
.
3.00
3.00
0.31-28.84
0.97-9.30
0.341
0.057
3.00
1.00
0.81-11.08
0.40-2.52
0.10
1.00
3.00 / 3.00 = 1.00
3.00 / 1.00 = 3.00
.
    Gender
        Male
        Female
.
2.25
6.00
0.69-7.31
0.79-49.84
0.177
0.097
1.57
1.40
0.61-4.05
0.44-4.41
0.350
0.566
2.25 / 1.57 = 1.43
6.00 / 1.40 = 4.29
.
    Etiology
        Ischemic
        Non-ischemic
.
2.00
3.67
0.37-10.92
1.02-13.14
0.423
0.046
.
#
1.00
-
0.55-2.23
.
-
1.00
-
3.67 / 1.00 = 1.00
.
    LVSD
        Severe
        Non-severe
.
9.00
1.25
1.14-71.04
0.34-4.65
0.037
0.739
2.50
1.00
0.78-7.97
0.38-2.66
0.121
1.00
9.00 / 2.50 = 3.60
1.25 / 1.00 = 1.25
.
    Diabetes mellitus
        Yes 
        No
.
3.0
3.0
0.61-14-86
0.81-11.08
0.178
0.099
3.50
1.10
0.73-16.85
0.47-2.59
0.118
0.827
3.00 / 3.50 = 0.86
3.00 / 1.10 = 2.73
.
    Arterial hypertension
        Yes 
        No
.
2.25
6.00
0.69-7.31
0.72-49.84
0.177
0.097
1.33
2.00
0.56-3.16
0.50-8.00
0.514
0.327
2.25 / 1.33 = 1.69
6.00 / 2.00 = 3.00
.
    CKD
        Yes 
        No
.
2.00
3.67
0.37-10.92
1.02-13.14
0.423
0.046
2.00
1.00
0.60-6.64
0.32-3.10
0.258
1.00
2.00 / 2.00 = 1.00
3.67 / 1.00 = 3.67
.
    COPD
        Yes 
        No
.
0.67
6.50
0.11-3.99
1.47-28.80
0.657
0.014
1.25
#
0.59-2.67
-
0.565
-
0.67 / 1.25 = 0.54
-
.
    AF
        Yes 
        No
.
1.66
5.00
0.40-6.97
1.10-22.82
0.484
0.038
1.00
2.00
0.32-3.10
0.75-5.33
1.00
0.166
1.66 / 1.00 = 1.66
5.00 / 2.00 = 2.50
.
    Anemia
        Yes 
        No
.
2.50
3.33
0.49-12.89
0.92-12.11
0.273
0.067
2.00
1.25
0.60-6.64
0.49-3.17
0.258
0.638
2.50 / 2.00 = 1.25
3.33 /1.25 = 2.66
.
    ACEI
        Yes 
        No
.
4.50
2.00
0.97-20.83
0.50-8.00
0.054
0.327
1.20
3.00
0.52-2.77
0.61-14.86
0.670
0.178
4.50/ 1.20 = 3.75
2.00 / 3.00 = 0.67
.
    ARB
        Yes 
        No
.
4.00
2.75
0.45-35.79
0.88-8.64
0.215
0.083
4.00
1.27
0.45-35.79
0.58-2.80
0.215
 0.549
4.00 / 4.00 = 1.00
2.75 / 1.27 = 2.17
.
    BB
        Yes 
        No
.
5.50
1.33
1.22-24.81
0.29-5.96
0.027
0.706
1.70
0.50
0.78-3.71
0.05-5.51
0.183  
0.571
5.50 / 1.70 = 3.24
1.33 / 0.50 = 2.66
ACEI - angiotensin conversion enzyme inhibitors; ACS - acute coronary syndrome; AF - atrial fibrillation; ARB - angiotensin receptor block-
ers; BB - beta-blockers; CKD - chronic kidney disease; CI - confidence interval; COPD - chronic obstructive pulmonary Disease; IQR - inter-
quartile range; LVSD - left ventricular systolic dysfunction; OR - odds ratio. 
# - impossible to perform the calculation due to the absence of discordant pairs.
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Figure 1 – Case-time-control study design: case and control case-crossover and exposure time 
periods considered. HF - heart failure; OR - odds ratio.
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Figure 2 – Flowchart of the selection of patients included in the case and control arms of the case-
time-control study. HF - heart failure.
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6. CONCLUSIONS
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According to our study, an adherence rate below 88% dose-counts of loop diuretic in chronic HF 
patients doubles the risk of decompensation in the following week.
This triggering effect was stronger among older patients, in women, with severe LVSD, without risk 
factors and comorbidities and under treatment with ACEI. 
The identification of these profiles may enable the timely application of adherence improvement 
measures.
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
7. REFERENCES
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
1.	 WHO, Global status report on noncommunicable disaeses 2010. Geneva. 2011.
2.	 WHO, Global Atlas on cardiovascular disease prevention and control. Geneva. 2011.
3.	 Cleland JGF, Khand A, Clark A.The heart failure epidemic: exactly how big is it? Eur Heart J, 
2001. 22: p. 623-626.[PMID: 11286518]
4.	 Task force of the working group on Heart Failure of the European Society of Cardiology. The 
treatment of heart failure. Eur Heart J, 1997. 18: p. 736-753. [PMID: 915264]
5. McMurray JJ, A.S., Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, 
Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, 
Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, 
Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines., ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart 
J, 2012. 33(14): p. 1787-847. [PMID: 22611136; doi: 10.1093/eurheartj/ehs104].
6.	 McMurray JJV, Pfeffer MA. Heart failure. Lancet, 2005. 365: p. 1877-89. [PMID: 15924986]
7.	 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Peterson 
PN, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Riegel B, Sam F, 
Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; ACCF/AHA Task Force Members., 2013 
ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College 
of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Am Col l Card io l , 2013  OCT 15:62(16) :e147-239. [PMID: 23747642; DOI : 
10.1016/j.jacc.2013.05.019]
8.	 Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart, 2007. 93: p. 1137-1146. 
[PMID: 17699180].
9.	 Nohria A, Lewia E, Stevenson LW. Medical management of advanced heart failure. JAMA, 
2002. 287: p. 628-640.[PMID: 11829703].
10.	 Cleland JG, Torabi A, Khan NK. Epidemiology and management of heart failure and left 
ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart, 2005. 91 
Suppl 2: p. ii7-13; discussion ii31, ii43-8.[PMID: 15831613]
11.	 Singer AJ, Skopiki H, Thode HC Jr, Peacock WF. Hemodynamic profiles of ED patients with 
acute decompensated heart failure and their association with treatment. Am J Emerg Med, 
2014. 32(4): p. 302-5. [PMID: 24412023; doi: 10.1016/j.ajem.2013.12.005].
12.	 Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J 
Heart Fail, 1999. 1: p. 229-41.[PMID: 10935669].
13.	 Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: neglected or 
misdiagnosed? JACC, 2002. 39(1): p. 138-41.[PMID: 11755299].
14.	 Selby VN, Teerlink JR. What's new in the treatment of acute heart failure? Curr Cardiol Rep, 
2013. 15(9): p. 393. [PMID: 23881577; doi: 10.1007/s11886-013-0393-z].
15. Graziani G, Pini D, Oldani S, Cucchiari D, Podestà MA, Badalamenti S. Renal dysfunction in 
acute congestive heart failure: a common problem for cardiologists and nephrologists. Heart 
Fail Rev, 2013.[PMID: 24297366]
16.	 Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart 
failure with preserved ejection fraction. Eur J Heart Fail, 2011. 13: p. 18-28. [PMID: 20685685; 
doi: 10.1093/eurjhf/hfq121].
17.	 Metanalysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with 
heart failure with preserved or reduced left ventricular ejection fraction - an individual patient 
data meta-analysis. Eur Heart J, 2012. 33: p. 1750-1757. [PMID: 21821849; doi: 
10.1093/eurheartj/ehr254].
18. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? 
Five-year survival following a first admission for heart failure. Eur J Heart Fail, 2001. 3: p. 
315-322. [PMID: 11378002].
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
19.	 Roush GC, Kaur R,  Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther, 
2014. 19(1): p. 5-13. [PMID: 24243991; doi: 10.1177/1074248413497257].
20.	 Filippatos G, Farmakis D, Bistola V, Karavidas A, Mebazaa A, Maggioni AP, Parissis JT. 
Temporal trends in epidemiology, clinical presentation and management of acute heart failure: 
results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard 
Treatment and the European Society of Cardiology-Heart Failure pilot survey. Eur Heart J 
Acute Cardiovasc Care, 2014. [PMID: 2459524].
21. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, 
Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, 
Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, 
Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol 
G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, 
Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke 
Statistics Subcommittee.  Heart Disease and Stroke Statistics−−2013  Update: A Report From 
the American Heart Association. Circulation, 2013. 127: p. e6-e245. [PMID: 23283859; doi: 
10.1161/CIR.0b013e318282ab8f].
22.	 Heidenreich PA, T.J., Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, 
Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PWF, Woo 
YJ; on behalf of the American Heart Association Advocacy Coordinating Committee, Stroke 
Council, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, 
Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and 
Vascular Biology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, 
Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, Council 
on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care 
and Outcomes Research. Forecasting the future of cardiovascular disease in the United 
States: a policy statement from the American Heart Association. Circulation, 2011. 123: p. 
933-944. [PMID: 2126299; doi: 10.1161/CIR.0b013e31820a55f5.].
23.	 WHO, The global burden of disease - 2004 update. Geneve. 2008. 
24.	 Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, 
Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study. Lifetime risk for developing 
congestive heart failure - The Framingham Heart Study. Circulation, 2002. 106: p. 3068-3072. 
[PMID: 12473553].
25.	 Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, Burke GL, Lima JA., Differences 
in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of 
atherosclerosis. Arch Intern Med, 2008. 168(19): p. 2138-2145. [PMID: 18955644; doi: 
10.1001/archinte.168.19.2138].
26.	 Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and 
survival (from the Atherosclerosis Risk in Communities Study). Am J Cardiol, 2008. 101: p. 
1016-1022. [PMID: 18359324; doi: 10.1016/j.amjcard.2007.11.061].
27.	 Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a 
well-defined older population. Circulation, 2006. 113: p. 799-805. [PMID: 16461823].
28.	 Bibbins-Domingo K, Pletcher MJ, Lin F, Vittinghoff E, Gardin JM, Arynchyn A, Lewis CE, 
Williams OD, Hulley SB. Racial differences in incident heart failure among young adults. N Engl 
J Med, 2009. 360(12): p. 1179-90. [PMID: 19297571; doi: 10.1056/NEJMoa0807265].
29.	 Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen 
SJ.,Trends in heart failure incidence and survival in a community-based population. JAMA, 
2004. 292: p. 344-350. [PMID: 15265849].
30.	 Kociol RD, Hammill BG, Fonarow GC, Klaskala W, Mills RM, Hernandez AF, Curtis LH. 
Generalizability and longitudinal outcomes of a national heart failure clinical registry: 
Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and 
non-ADHERE Medicare beneficiaries. Am Heart J, 2010. 160(5): p. 885-92. doi: [PMID: 
21095276; 10.1016/j.ahj.2010.07.020].
31.	 Giamouzis G, Kalogeropoulos A, Georgiopoulo V, Laskar S, Smith AL, Dunbar S, Triposkiadis 
F, Butler J. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, 
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
knowledge gaps, and future directions. J Card Fail, 2011. 17(1): p. 54-75. [PMID: 21187265; 
doi: 10.1016/j.cardfail.2010.08.010]
32.	 Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND, Roger VL. 
Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol, 
2009. 54(18): p. 1695-702. [PMID: 19850209; doi: 10.1016/j.jacc.2009.08.019].
33.	 Levy D, Kenchaiah S, LArson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. 
Long-term trends in the incidence of and survival with heart failure. . N Engl J Med, 2002. 
347(18): p. 1397-402. [PMID: 12409541].
34.	 Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 
1979 to 2004. J Am Coll Cardiol, 2008. 52(6): p. 428-34. [PMID: 18672162; doi: 
10.1016/j.jacc.2008.03.061].
35. Curtis LH, Greiner MA, Hammill BG, Kramer JM, Whellan DJ, Schulman KA, Hernandez AF. 
Early and long-term outcomes of heart failure in elderly persons, 2001–2005. Arch Intern Med, 
2008. 168: p. 2481– 8. [PMID: 19064833; doi: 10.1001/archinte.168.22.2481].
36.	 Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M Yancy; ADHERE Scientific Advisory 
Comittee and Investigators. Temporal trends in clinical characteristics, treatments, and 
outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated 
Heart Failure National Registry (ADHERE). Am Heart J, 2007. 153(6): p. 1021-8. [PMID: 
17540205].
37. West R, Laing L, Fonarow GC, Kociol R, Mills RM, O’Connor CM, Hernandez AF. 
Characterization of heart failure patients with preserved ejection fraction: a comparison 
between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail, 2011. 
13(9): p. 945-52. [PMID: 21712289; doi: 10.1093/eurjhf/hfr064].
38.	 Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, 
Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and 
Investigators., Characteristics and outcomes of patients hospitalized for heart failure in the 
United States: Rationale, design, and preliminary observations from the first 100,000 cases in 
the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J, 2005. 149: 
p. 209-16. [PMID: 15846257].
39.	 Baggish AL, van Kimmenade R, Bayes-Genis A, Davis M, Lainchbury JG, Frampton C, Pinto 
Y,  Richards MA, Januzzi JL. Hemoglobin and N-terminal pro-brain natriuretic peptide: 
Independent and synergistic predictors of mortality in patients with acute heart failure Results 
from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta, 2007. 381(2): 
p. 145-50. [PMID: 17445789].
40. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, Fonarow GC, DeMarco T, 
Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM., 
Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe 
Heart Failure in the ESCAPE Trial. Arch Intern Med, 2007. 167(18): p. 1998-2005.[PMID: 
17923601].
41.	 Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospitalization in 
patients with heart failure discharged from Scottish hospitals  in 1995. Eur Heart J, 1998. 19: 
p. 1063-9. [PMID: 971704].
42.	 Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu Aw. 
Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare 
beneficiaries with chronic heart failure. Journal of the American College of Cardiology, 2003. 
42(7): p. 1226-1233.[PMID: 14522486].
43.	 Lesman-Leegte I, Jaarma T, Coyne JC, Hillege HL, Van Veldhuisen DJ, Sanderman R. Quality 
of life and depressive symptoms in the elderly: a comparison between patients with heart 
failure and age- and gender-matched community controls. J Cardiac Fail, 2009. 15(9): p. 
17-23. [PMID: 19181289; doi: 10.1016/j.cardfail.2008.09.006].
44.	 Moser DK, Yamokoski L, Sun JL, Conway GA, Hartman KA, Graziano JA, Binanay C, 
Stevenson LW; Escape Investigators. Improvement in health-related quality of life after 
hospitalization predicts event-free survival in patients with advanced heart failure. J Cardiac 
Fail, 2009. 15(9): p. 763-769. [PMID: 19879462; doi: 10.1016/j.cardfail.2009.05.003].
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
45.	 Hellermann JP, Goraya TY, Jacobsen SJ, Weston SA, Reeder GS, Gersh BJ, Redfield MM, 
Rodeheffer RJ, Yawn BO, Roger VL. Incidence of Heart Failure after Myocardial Infarction: Is It 
Changing over Time? American Journal of Epidemiology, 2003. 157(12): p. 1101-1107.[PMID: 
12796046].
46.	 Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of 
men--morbidity, risk factors and prognosis. J Intern Med, 2001. 249(3): p. 253-61. [PMID: 
11285045].
47.	 Baker DW. Prevention of heart failure. J Card Fail, 2002. 8: p. 333-46.[PMID: 12411985].
48.	 Taegtmeyer H, McNulty P, Young ME. Adaptation and Maladaptation of the Heart in Diabetes: 
Part I: General Concepts. Circulation, 2002. 105(14): p. 1727-1733. [PMID: 11940554].
49.	 He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive 
heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern 
Med., 2001. 161: p. 996-1002.[PMID: 11295963].
50.	 Krumholz HM, Amatruda J, Smith GL, Mattera JA, Roumanis SA, Radford MJ, Crombie P, 
Vaccarino V. Randomized Trial of an Education and Support Intervention to Prevent 
Readmission of Patients With Heart Failure. JACC, 2002. 39(1): p. 83-9.[PMID: 11755291].
51.	 Wu MY, Chang NC, Su CL, Hsu YH, Chen TW, Lin YF, Wu CH, Tam KW. Loop diuretic 
strategies in patients with acute decompensated heart failure: a meta-analysis of randomized 
control led tr ials. J Crit Care, 2014. 29(1): p. 2-9. [PMID: 24331943; doi: 
10.1016/j.jcrc.2013.10.009].
52.	 Bleasdale RA, Frenneaux MP. Cardiac resynchronisation therapy: when the drugs don't work. 
Heart, 2004. 90 Suppl 6: p. vi2-4. [PMID: 15564421].
53.	 Mann DL. Left Ventricular Size and Shape: Determinants of Mechanical Signal Transduction 
Pathways. Heart Failure Review, 2005. 10: p. 95-100.[PMID: 16258716 ].
54.	 Anker SD, Negassa A, COats AK, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic 
importance of weight loss in chronic heart failure and the effect of treatment with 
angiotensin-converting-enzyme inhibitors: an observational study. The Lancet, 2003. 
361(9363): p. 1077-1083.[PMID: 12672310].
55.	 O'Connor CM, Joynt KE. Depression: are we ignoring an important comorbidity in heart 
failure? J Am Coll Cardiol, 2004. 43(9): p. 1550-2.[PMID: 15120810].
56.	 McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: 
prognostic and therapeutic implications from a prospective cohort study. Circulation, 2004. 
109(8): p. 1004-9. [PMID: 14769700]
57. McMurray JJ, A.S., Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, 
Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, 
Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, 
Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines., ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: Addenda. 
Eur Heart J, 2012. 33(14): p. 1787-847. [PMID: 22611136; doi: 10.1093/eurheartj/ehs104.].
58.	 Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M Ghali WA, Knudtson ML; 
APPROACH Investigators.The association among renal insufficiency, pharmacotherapy, and 
outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol, 
2004. 44(8): p. 1587-92.[PMID: 15489090].
59.	 Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van 
der Meer P. Anemia and mortality in heart failure patients a systematic review and 
meta-analysis. J Am Coll Cardiol, 2008. 52(10): p. 818-27.[PMID: 18755344; doi: 
10.1016/j.jacc.2008.04.061.].
60.	 Angermann CE. Comorbidities in heart failure: a key issue. European Journal of Heart Failure 
Supplements, 2009. 8(Supplement 1): p. i5-i10.
61.	 Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. J Card Fail, 2005. 
11(6): p. 455-63.[PMID: 1610563].
62.	 Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and 
treatment options. Circulation, 2006. 113(20): p. 2454-61.[PMID: 16717164]
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
63. Mascarenhas J, Lourenço P, Lopes R, Azevedo A, Bettencourt P. Chronic obstructive pulmo-
nary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 
2008 Mar;155(3):521-5. [PMID: 18294490; doi: 10.1016/j.ahj.2007.10.040.].
64. Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, O’Connor; 
SADHART-CHF Investigators. Characteristics of depression remission and its  relation with 
cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF 
Study) . Am J Card io l , 2011. 107(4) : p. 545-51. [PMID: 21295172; do i : 
10.1016/j.amjcard.2010.10.013]
65.	 Moser DK, Dracup K, Evangelista LS, Zambroski CH, Lennie TA, Chung ML, Doering LV, 
Westlake C. Comparison of prevalence of symptoms of depression, anxiety, and hostility in 
elderly patients with heart failure, myocardial infarction, and a coronary artery bypass graft. 
Heart Lung, 2010. 39(5): p. 378-85. [PMID: 20561849; doi: 10.1016/j.hrtlng.2009.10.017.].
66.	 York KM, Hassan M, Sheps DS. Psychobiology of depression/distress in congestive heart 
f a i l u re . Hea r t Fa i l Rev, 2009 . 14 (1 ) : p . 35 -50 . [PM ID : 18368481 ;do i : 
10.1007/s10741-008-9091-0].
67.	 Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart 
failure: which features are any use? Q J Med, 1997. 90: p. 33-339.[PMID: 9205668].
68.	 Khunti K, Baker R, Grimshaw G. Diagnosis of patients with chronic heart failure in primary 
care: usefulness of history, examination, and investigations. Br J Gen Pract, 2000. 50(450): p. 
50-4.[PMID: 1069507].
69.	 Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE. Utility of 
History, Physical Examination, Electrocardiogram, and Chest Radiograph for Differentiating 
Normal from Decreased Systolic Function in Patients with Heart Failure. Am J Med, 2002. 
112: p. 437-445.[PMID: 11959053].
70. Bettencourt P, Friões F, Azevedo A, Dias P, Pimenta J, Rocha-Gonçalves F, Ferreira A., 
Prognostic information provided by serial measurements of brain natriuretic peptide in heart 
failure. Int J Cardiol, 2004. 93: p. 45-48. [PMID: 14729434].
71.	 Cowie MR, Struthers AD, Wood DA, COats AJ, Thompson SG, Poole-Wilson PA, Sutton GC- 
Value of natriuretic peptides in assessment of patients with possible new heart failure in 
primary care. The Lancet, 1997. 350(9088): p. 1349-1353. [PMID: 9365448].
72.	 Yamamoto K, Burnett JC Jr, Bermudez EA, Jougasaki M, Bailey Kr, Redfield MM. Clinical 
criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail, 2000. 
6(3): p. 194-200. [PMID: 10997744]
73.	 Fuat A, Murphy JJ, Hungin AP, Curry J, Mehrzad AA, Hetherington A, Johnston JI, Smellie 
WS, Duffy V, Cawley P., The diagnostic accuracy and utility of a B-type natriuretic peptide test 
in a community population of patients with suspected heart failure. Br J Gen Pract, 2006. 
56(526): p. 327-33.[PMID: 16638247].
74.	 Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic 
research: what, why, and how? BMJ, 2009. 338: p. b375. [PMID: 19237405;doi: 
10.1136/bmj.b375.].
75.	 Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog 
Cardiovasc Dis, 2011. 54(2): p. 86-96. [PMID: 21875508; doi: 10.1016/j.pcad.2011.03.003].
76.	 Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E. The 
association of hemoglobin A1c with Incident heart failure among people without diabetes: the 
atherosclerosis risk in communities study. Diabetes, 2010. 59: p. 2020-2026. [PMID: 
20484138; doi: 10.2337/db10-0165.].
77.	 Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeifer MA, Swedberg K, Wang D, 
Yusuf S, Michelson EL, Granger CB; CHARM Invstigators. Red cell distribution width as a 
novel prognostic marker in heart failure: data from the CHARM Program and the Duke 
Databank. J Am Coll Cardiol, 2007. 50(1): p. 40-7. [PMID: 17601544].
78.	 Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeifer MA, Swedberg K, Wang D, Yusuf S, 
Michelsen EL, Granger CB; CHARM Investigators. Liver function abnormalities and outcome in 
patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of 
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail, 2009. 11(2): p. 
170-7.  [PMID: 19168515 ; doi: 10.1093/eurjhf/hfn031.].
79.	 Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger 
CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators and 
Committees.,Albuminuria in chronic heart failure: prevalence and prognostic importance. 
Lancet, 2009. 374: p. 543-50. [PMID: 19683640; doi: 10.1016/S0140-6736(09)61378-7.].
80.	 Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedeberg KB, Ostergren J, 
Michelsen EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with 
chronic heart failure. Eur Heart J, 2006. 27(1): p. 65-75.[PMID: 16219658]
81.	 Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets 
D, Massie BM. Factors associated with outcome in heart failure with preserved ejection 
fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study 
(I-PRESERVE). Circ Heart Fail, 2011. 4(1): p. 27-35. [PMID: 21068341; doi: 
10.1161/CIRCHEARTFAILURE.109.932996].
82.	 Frazier CG, Alexander KP, Newby LK, Anderson S, Iverson E, Packer M, Cohn J, Goldstein S, 
Douglas PS.  Associations of gender and etiology with outcomes in heart failure with systolic 
dysfunction: a pooled analysis of 5 randomized control trials. J Am Coll Cardiol, 2007. 49: p. 
1450-1458. [PMID: 17397674].
83.	 Parashar S, Katz R, Smith NL, Arnold AM, Vaccarino V, Wenger NK, Gottdiener JS. Race, 
gender, and mortality in adults > or =65 years of age with incident heart failure (from the 
Cardiovascular Health Study). Am J Cardiol, 2009. 103(8): p. 1120-7. [PMID: 19361600; doi: 
10.1016/j.amjcard.2008.12.043.].
84.	 Roberts CB, Couper DJ, Chang PP, James SA, Rosamond Wd, Heiss G. Influence of 
life-course socioeconomic position on incident heart failure in blacks and whites: the 
Atherosclerosis Risk in Communities Study. Am J Epidemiol, 2010. 172(6): p. 717-27. [PMID: 
20696652; doi: 10.1093/aje/kwq193.].
85.	 Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM, Rathore SS, 
Krumholz HM. Race and renal impairment in heart failure: mortality in blacks versus whites. 
Circulation, 2005. 111(10): p. 1270-7.[PMID: 15769768].
86.	 Felker GM, Thompson RE, Hare JM, Hruban RH, Clemeston DE, Howard DL, Baughman KL, 
Kasper EK. Underlying causes and long-term survival in patients with initially unexplained 
cardiomyopathy. N Engl J Med, 2000. 342: p. 1077-1084.[PMID: 10760308].
87.	 Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional 
cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol, 2004. 43(8): 
p. 1439-44.[PMID: 15093881].
88.	 Fonarow GC, Srikanthan P, Constanzo MR, Cintron GB, Lopatin; ADHERE Scientific Advisory 
Committee and Investigators, An obesity paradox in acute heart failure: analysis of body mass 
index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure 
National Registry. Am Heart J, 2007. 153(1): p. 74-81.[PMID: 17174642].
89.	 Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJS. Diuretics for heart failure. , 
Diuretics for heart failure (Review). Cochrane Database of Systematic Reviews, 2012(2). 
[PMID: 22336795; doi: 10.1002/14651858.CD003838.pub3.].
90.	 Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown 
MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. 
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced 
ejection fraction. N Engl J Med, 2002. 346: p. 877-883. [PMID: 11907286].
91.	 Lindenfeld J, Feldman AM, SAxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, 
Steinberg JS, Laski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Effects of 
cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations 
in patients with New York Heart Association class IV heart failure. Circulation, 2007. 115(2): p. 
204-12.[PMID: 17190867].
92.	 Hobbs FD, Roalf AK, Davis RC, Davies MK, Hare R; Midlands Research Practices Consortium 
(MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic 
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening 
Study (ECHOES). Eur Heart J, 2007. 28(9): p. 1128-34.[PMID: 17459902]
93.	 Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, 
Michelson EL, Wang J, Pocock S, Pfeffer MA; Candesartan in Heart FAilute Reduction in 
Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a 
broad spectrum of heart failure patients. Circulation, 2005. 112(24): p. 3738-44. [PMID: 
16330684].
94.	 Hsich E, Gorodeski EZ, Starling RC, Blackstone EH, Ishwaran H, Lauer MS. Importance of 
treadmill exercise time as an initial prognostic screening tool in patients with systolic left 
ventricular dysfunction. Circulation, 2009. 119(25): p. 3189-97. [PMID: 19528334; doi: 
10.1161/CIRCULATIONAHA.109.848382.].
95.	 O'Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of 
death in patients with heart failure receiving beta-blockers. Circulation, 2005. 111(18): p. 
2313-8.[PMID: 15867168].
96.	 Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, 
Bhalla MA, Bhalla V, Clopton P, Jesse R; Rapid Emergency Department Heart Failure 
Outpatien Trial Investigators. Primary results of the Rapid Emergency Department Heart Failure 
Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency 
department decision making, and outcomes in patients presenting with shortness of breath. J 
Am Coll Cardiol, 2004. 44(6): p. 1328-33. [PMID: 15364340].
97.	 Anand I, McMurray JJ, Withmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia 
and its relationship to clinical outcome in heart failure. Circulation, 2004. 110(2): p. 
149-54.[PMID: 1521059].
98.	 Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ., The current cost of 
heart failure to the National Health Service in the UK. Eur J Heart Fail, 2002. 4: p. 361-371. 
[PMID: 12034163].
99.	 Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN; Val-HeFT 
Investigators., Prognostic value of changes in N-terminal pro-brain natriuretic peptide in 
Val-HeFT (Valsartan Heart Failure Trial). JACC, 2008. 52(12): p. 997-1003. [PMID: 18786480; 
doi: 10.1016/j.jacc.2008.04.069.].
100.	 Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, 
Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN; Val-HeFT Heart Failure Trial 
Investigators., Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT 
echocardiographic study. JACC, 2002. 40(5): p. 970-5. [PMID: 12225725].
101.	 Ekman I, Cleland JG, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. 
Eur J Heart Fail, 2005. 7: p. 699-703. [PMID: 1608712],
102.	 Goebel JAm Van Bakel AB. Rational use of diuretics in acute decompensated heart failure. 
Curr Heart Fail Rep, 2008. 5: p. 153-162. [PMID: 18752765].
103.	 Brater DC. Diuretic therapy. N Engl J Med, 1998. 339(6): p. 387-95. [PMID: 9691107].
104.	 Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology, 2009. 96: p. 
132-143. [PMID: 11805380].
105.	 Gupta S, Neyses L. Diuretic usage in heart failure - a continuing conundrum in 2005. Eur 
Heart J, 2005. 26: p. 644-649.[PMID: 15734765].
106.	 Silke B. Diuretic induced changes in symptoms and quality of life. Br Heart J, 1994. 72 
(Supplement): p. S57-62. [PMID: 7946762].
107.	 Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting 
the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J 
Cardiol, 2002. 82(2): p. 149-58. [PMID: 11853901]
108.	 Hampton JR. Results of clinical trials with diuretics in heart failure. Br Heart J, 1994. 72 
(Supplement): p. S68-72. [PMID: 7946764].
109.	 Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in 
advanced heart failure. Am J Cardiol, 2006. 97: p. 1759-1764. [PMID: 16765130].
110.	 Jhund PS, McMurray JJ, Davie AP. The acute vascular effects of frusemide in heart failure. Br 
J Clin Pharmacol, 2000. 50: p. 9-13. [PMID: 10886111].
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
111.	 Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ. Renal and extrarenal 
hemodynamic effects of furosemide in congestive heart failure after acute myocardial 
infarction. N Engl J Med, 1973. 288: p. 1087-1090.[PMID: 4697939].
112.	 Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN., Acute vasoconstrictor 
response to intravenous furosemide in patients with chronic congestive heart failure activation 
of the neurohumoral axis. Ann Intern Med, 1985. 103(1): p. 1-6. [PMID: 2860833].
113.	 Braunschweig F, Linde C, Eriksson MJ, Hofman-Bang C, Ryden L. Continuous 
haemodynamic monitoring during withdrawal of diuretics in patients with congestive heart 
failure. Eur Heart J, 2002. 23: p. 59-69. [PMID: 11741363].
114.	 Packer M. Why do the kidneys release renin in patients with congestive heart failure? A 
nephrocentric view of convertingenzyme inhibition. Eur Heart J, 1990. 11(Suppl D): p. 44-52. 
[PMID: 2193810].
115.	 Jonhston GD, Nicholis DP, Leahey WJ. The dose-response characteristics of the acute 
non-diuretic peripheral vascular effects of frusemide in normal subjects. Br J Clin Pharmac, 
1984. 18: p. 75-81. [PMID: 6378234].
116.	 Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, 
Greenberg B, Quinones MA, Yusuf S. Comparative neurohormonal responses in patients with 
preserved and impaired left ventricular ejection fraction: results of the Studies of Left 
Ventricular Dysfunction (SOLVD) registry. The SOLVD Investigators. J Am Coll Cardiol, 1993. 
22(Suppl A): p. 146A-153A. [PMID: 8376686].
117.	 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect 
of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J 
Med, 1999. 341(10): p. 709-17.[PMID: 10471456].
118.	 Mukherjee D. Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? Con-
gest  Heart Fail. 2008 Mar-Apr;14(2):75-82. Review. [PMID: 18401215].
119.	 Aneja A, Farkouh ME. Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or 
edema?  Ther Adv Cardiovasc Dis. 2008  Feb;2(1):53-66. doi: 10.1177/1753944707088184. 
Review. [PMID: 19124408; doi: 10.1177/1753944707088184.]
120. Huerta C, Varas-Lorenzo C, Castellsague J, García Rodríguez LA. Non-steroidal anti-
inflammatory drugs and risk of first hospital admission for heart failure in the general popula-
tion. Heart. 2006 Nov;92(11):1610-5. Epub 2006 May 22.[PMID: 16717069 ].
121.	 Dormans TP, Gerlag P. Combination of high-dose furosemide and hydrochlorothiazide in the 
treatment of refractory congestive heart failure. Eur Heart J, 1996. 17: p. 1867-1874.[PMID: 
8960430].
122.	 Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of 
loop diuretics in congestive heart failure. Cochrane Database of Syst Rev. 2005 Jul 
20;(3):CD003178.[PMID: 16034890].
123.	 Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, 
Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, 
Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, 
O'Connor CM; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients 
with acute decompensated heart failure. N Engl J Med, 2011. 364: p. 797-805. [PMID: 
21366472; doi: 10.1056/NEJMoa1005419].
124. Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy 
of loop diuretics even in patients with advanced renal failure. Kidney Int, 1994. 46: p. 
482-488.[PMID: 7967362].
125.	 Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents 
for resistant sodium retention. Ann Intern Med, 1983. 99(3): p. 405-6.[PMID: 6614693].
126.	 Gustafsson F, Arnold JM. Heart failure clinics and outpatient management: review of the 
evidence and call for quality assurance. . Eur Heart J, 2004. 25: p. 1596-1604.[PMID: 
15351158]
127.	 Azevedo A, Pimenta J, Dias P, Bettencourt P, Ferreira A, Cerqueira-Gomes M., Effect of a 
heart failure clinic on survival and hospital readmission in patients discharged from acute 
hospital care. Eur J Heart Fail, 2002. 4: p. 353-359.[PMID: 12034162].
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
128.	 Feenstra J, Grobbee DE, Jonkman FAM, Hoes AW, Stricker BH. Prevention of relapse in 
patients with congestive heart failure. Heart, 1998. 80: p. 432-436. [PMID: 9930039].
129.	 Porta M. A Dictionary of Epidemiology. 5th edition, Oxford University Press, New York. 2008.
130.	 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med, 2005. 353: p. 487-97. 
[PMID: 16079372].
131.	 Steiner JF, Earnest MA, The language of medication-taking. Ann Intern Med, 2000. 132: p. 
926-30. [PMID: 10836931].
132.	 Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, 
Michelson EL, Pfeffer MA; CHARM investigators., Adherence to candesartan and placebo and 
outcomes in chronic heart failure in the CHARM programme- doubleblind, randomised, 
controlled clinical trial. Lancet, 2005. 366: p. 2005-11.[PMID: 16338449].
133.	 Jackevicius CA, Mandani M, Tu JV., Adherence with statin therapy in elderly patients with and 
without acute coronary syndromes. JAMA, 2002. 288: p. 462-7. [PMID: 12132976]
134.	 Cramer J, Roseheck R, Kirk G, Krol W, Krystal J; VA Naltrexone Study Group 425. Medication 
compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health, 
2003. 6(5). [PMID: 14627063].
135.	 Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment - clinical 
applications. JAMA, 2002. 288: p. 2880-2883. [PMID: 12472330].
136.	 Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose 
regimens and medication compliance. Clin Ther, 2001. 23: p. 1296-310. [PMID: 11558866].
137. Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, Ma Y, Kaplan AH, Wenger NS. How 
well do clinicians estimate patients’ adherence to combination antiretroviral therapy? J Gen 
Intern Med, 2002. 17: p. 1-11. [PMID: 11903770].
138.	 Murri R, Ammassari A, Trotta MP, De Luca A, Melzi S, Minardi C, Zaccarelli M, Rellecati P, 
Santopadre P, Soscia F, Scasso A, Tozzi V, Ciardi M, Orofino GC, Noto P, Monforte Ad, 
Antinori A, Wu AW; AslCoNa Study Group. Patient-reported and physician-estimated 
adherence to HAART- social and clinic center- related factors are associated with 
discordance. J Gen Intern Med, 2004. 19: p. 1104-10. [PMID: 15566439].
139.	 Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure- symptoms, patterns 
of onset, and contributing factors. Am J Med, 2003. 114: p. 625-30.[PMID: 12798449].
140.	 The Coronary Drug Project Research Group. Influence of adherence to treatment and 
response of cholesterol mortality in the coronary drug project. N Engl J Med, 1980. 303: p. 
1038-41. [PMID: 6999345].
141.	 Golin CE, Liu H, Hays RD, Miller LG, Becl CK, Ickovics J, Kaplan AH, Wenger NS. A 
prospective study of predictors of adherence to combination antiretroviral medication. J Gen 
Intern Med, 2002. 17: p. 756-65.[PMID: 1239055].
142.	 Black HR. Will better-tolerated antihypertensive agents improve blood pressure control? JNC 
VI revisited. Am J Hypertens, 1999. 12: p. 225S-230S.[PMID: 10619575].
143.	 Ickovics JR, Meade CS. Adherence to HAART among patients with HIV- breakthroughs and 
barriers. AIDS Care, 2002. 14: p. 309-18.[PMID: 12042076].
144.	 Ellis  JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin 
adherence and discontinuation in primary and secondary prevention populations. J Gen Intern 
Med, 2004. 19: p. 638-45. [PMID: 15209602].
145.	 Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR; Adolescent Medicine 
HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency 
virus-infected adolescents. Arch Pediatr Adolesc Med, 2003. 157: p. 249-55.[PMID: 
12622674].
146.	 Opasich C, Febo O, Riccardi PG, Traversi E, Forni G, Pinna G, Riccardi R, Mortara A, Sanarico 
M, Cobelli F, Tavazzi L. Concomitant factors of decompensation in chronic heart failure. Am J 
Cardiol, 1996. 78: p. 354-7. [PMID: 8759821].
147.	 Ambardekar AV, Fonarow GC, Hernandez AF, Pan W, Yancy CW, Krantz MJ; Get With the 
Guidelines Steering Committee and Hospitals., Characteristics and in-hospital outcomes for 
nonadherent patients with heart failure - findings from Get With the Guidelines - Heart Failure 
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
(GWTG_HF) . Am Hear t J , 2009. 158: p. 644-52. [PMID: 19781426;do i : 
10.1016/j.ahj.2009.07.034].
148. Krantz MJ, Havranek EP, Haynes DK, Smith I, Bucher-Bartelson B, Long CS. Inpatient 
initiation of β-blockade plus nurse management in vulnerable heart failure patients - a 
randomized study. J Cardiac Fail, 2008. 14: p. 303-9. [PMID: 18474343; doi: 
10.1016/j.cardfail.2007.12.008.]
149. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Grenberg BH, O’Connor 
CM, Pieper K, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigatros and Hospitals. 
Association between performance measures and clinical outcomes for patients hospitalized 
with heart failure. JAMA, 2007. 297: p. 61-70. [PMID: 17200476].
150. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Grenberg BH, O’Connor 
CM, Pieper K, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigatros and Hospitals. 
Factors identified as precipitating hospital admissions for heart 35 failure and clinical 
outcomes: findings from OPTIMIZE-HF. Arch Intern Med, 2008(168): p. 847-54. [PMID: 
18443260; doi: 10.1001/archinte.168.8.847].
151. Michalsen A, König G, Thimme W. Preventable and causative factors leading to hospital 
admission with decompensated heart failure. Heart, 1998. 80: p. 437-441.[PMID: 9930040].
152.	 Tsuyuki  RT, McKelvie RS, Amold  JM, Avezum A Jr, Barretto AC, Carvalho AC, Isaac DL, 
Kitching AD, Piegas LS, Teo KK, Yusuf S. Acute precipitants of congestive heart failure 
exacerbations. Arch Intern Med, 2001. 161(19): p. 2337-2342.[PMID: 11606149].
153.	 Leventhal MJE, Riegel B, Carlson B, DeGeest S. Negotiating Compliance in Heart Failure- 
Remaining Issues and Questions. Eur J Cardiovasc Nurs, 2005. 4. [PMID: 15893959].
154.	 Wu JR, Moser DK, De Jong MJ, Rayens MK, Chung ML, Riegel B, Lennie TA. Defining an 
evidence-based cutpoint for medication adherence in heart failure. Am Heart J, 2009. 157(2): 
p. 285-91. [PMID: 19185635;doi: 10.1016/j.ahj.2008.10.001].
155.	 Wu JR, Moser DK, Chung ML, Lennie TA. Predictors of medication adherence using a 
multidimensional adherence model in patients with heart failure. J Cardiac Fail, 2008. 14: p. 
603-614. [PMID: 18722327; doi: 10.1016/j.cardfail.2008.02.011.].
156.	 Etminan M, Samii A. Pharmacoepidemiology I: A Review of Pharmacoepidemiologic Study 
Designs. Pharmacotherapy, 2004. 24(8).[PMID: 15338844].
157.	 Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, Wellenius GA. Future cases as 
present controls to adjust for exposure trend bias in case-only studies. Epidemiology, 2011. 
22(4): p. 568-74. [PMID: 21577117]
158. Schneeweiss S, Stürmer T, Maclure M. Case-crossover and case-time control designs as 
alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf, 1997. 6 
Suppl. 3: p. S51-S59. [PMID: 15073755].
159.	 Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health, 
2000. 21: p. 193-221.[PMID: 10884952].
160.	 Rothman, K. Modern Epidemiology. Little Brown, Boston, 1986.
161.	 Suissa S. The case-time- control design. Epidemiology 1995. 6: p. 248-253.[PMID: 7619931]
162.	 Greenland S. A unified approach to the analysis  of case-distribution (case-only) studies. Statist 
Med, 1999. 18: p. 1-15.[PMID: 9990689].
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
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Figure 1 – Questionnaire for the evaluation of adherence to loop diuretic therapy in the case time 
period of exposure (case arm).
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Figure 2 – Questionnaire and visual aid for evaluation of adherence to loop diuretic therapy in the 
control time period of exposure (case arm).
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Figure 3 – Questionnaire for the evaluation of adherence to loop diuretic therapy in the case time 
period of exposure (control arm).
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Figure 4 – Questionnaire and visual aid for evaluation of adherence to loop diuretic therapy in the 
control time period of exposure (control arm).
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure       	
Marta Casal Moura 
Porto, Agosto 2014
2º ciclo de estudos em Epidemiologia
Low adherence to loop diuretic therapy as a trigger for decompensation in chronic heart failure        
